Top

Arlene O Siefker-Radtke, MD

Department of Genitourinary Medical Oncology, Division of Cancer Medicine

In the News

Blue test tubes, labeled with "FGFR-alterations, containing DNA strands

ASCO: Targeted therapy achieves responses across multiple cancer types with FGFR alterations

Line drawing of urinary system superimposed over torso shot of slender person in silk dress

Can frequent UTIs be a sign of bladder cancer?

ASCO: Updated targeted therapy clinical trials results continue to show improved outcomes for advanced colorectal and bladder cancers

New drug brings new hope for advanced bladder cancer

Present Title & Affiliation

Primary Appointment

Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Professor, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

Research Interests

Ongoing Research Support

Co-Investigator, 0.6 months, SPORE in Genitourinary Cancer, 2P50 CA91846, NIH/NCI, PI - Colin P. Dinney, 9/1/2011-8/31/2016 ($165,000/year)

Co-Investigator, 3%, Biology and Therapy of Basal Bladder Cancers, Cancer Prevention & Research Institute of Texas (CPRIT), 8/21/2014-8/30/2017, $822,309

Co-Investigator, 5%, Defining the biological and clinical properties of the p53-like/luminal A subtype for bladder cancer, The V Foundation for Cancer Research, 9/1/2014-8/31/2017, $640,000

Principal Investigator, Phase I Two -Dimensional Dose-Finding Study of Bortezomib in Combination with Gemcitabine/Doxorubicin in Metastatic Surgically Unresectable Urothelial Cancer or Other Solid Tumors, 2006-0014, 2006-2015, $40,000, Millennium, Inc.

Principal Investigator, A Phase 1 Study of Systemic Gene Therapy with SGT-94 in Patients with Solid Tumors, 2009-0825, 2010-2012 ($194,113/year), Synergene

Principal Investigator, A Phase I Two-Dimensional Dose-Finding Study of MLN9708 in Combination with Gemcitabine and Doxorubicin, Followed by a Phase II Extension to Assess the Efficacy of this Combination in Metastatic, Surgically Unresectable Urothelial Cancer, IISR-2013-M100190, 2014-present, $699,238, Millennium

World Leader Investigator, Phase 2, Two-arm Multicenter, Open-Label Study to Determine the Efficacy and the Safety of Two Different Dose Regimens of a pan-FGFR Tyrosine Kinase Inhibitor JNJ-42756493 in Subjects with Metastatic or Surgically Unresectable Urothelial Cancer with FGFR Genomic Alterations, JNJ-42756493/2015-0112, 2015-present, Janssen Research & Development LLC

Completed

Clinical Co-Leader, 2.4 months, Biology and Therapeutic Targeting of Epidermal Growth Factor Receptor in Bladder Cancer, 5 P50 CA091846 10, NIH/NCI, PI - Colin P Dinney, 9/25/2006-8/31/2012, $194,113

Co-Investigator, TRAIL receptor-based combination therapy for androgen-independent prostate cancer, PC074306P1, DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP), PI - David McConkey, 1/1/2009-12/31/2011, $250,000

Principal Investigator, A Phase II Clinical Trial of Neoadjuvant Chemotherapy with M-VAC Plus Avastin in Patients with Locally Advanced Urothelial Cancer, 2006-0620, 2007-2015, $318,000, Genentech

Education & Training

Degree-Granting Education

1996	The Johns Hopkins University School of Medicine, Baltimore, Maryland, US, MD
1992	Michigan State University, East Lansing, Michigan, US, Biochemistry, BS

Postgraduate Training

1999-2002	Clinical Fellowship, Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
1996-1999	Clinical Residency, Internal Medicine, Tufts New England Medical Center Hospital, Boston, Massachusetts

Board Certifications

2002	Medical Oncology
1999	Internal Medicine

Experience & Service

Academic Appointments

Associate Professor, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2010 - 2017

Assistant Professor, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2002 - 2010

Administrative Appointments/Responsibilities

Data Safety Monitoring Committee, Inaugural Chair, Department of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2020 - Present

Co-Leader, Department of Genitourinary Medical Oncology - Research, Core A, GU Clinical Trials and Oversite Bladder SPORE Committee, Houston, TX, 2015 - 2018

Clinical Co-Leader, Bladder SPORE Executive Committee, Houston, TX, 2006 - 2018

Committee Chair, The University of Texas M. D. Anderson Cancer Center Clinical Research Committee, Houston, TX, 2006 - 2009

Disease Site Liaison to the International Center, Department of International Center, The University of Texas MD Anderson Cancer Center, Houston, TX, 2005 - 2019

Other Appointments/Responsibilities

Bladder Cancer Committee Member for the 2022 SUO Scientific Program Planning Committee, Society of Urologic Oncology, San Diego, CA, 2022 - 2022

Steering Committee member, International Bladder Cancer Group, Houston, TX, 2021 - 2021

Member, Johns Hopkins Greenberg Bladder Cancer Institute External Advisory Board, Baltimore, MD, 2019 - Present

Member, NCCN Bladder/Penile Cancers Guidelines Panel representative for the McKesson Value Pathways, Fort Washington, PA, 2019 - 2021

Advisory Board, PanCanadian Urachal Cancer Study (PUCS) Urachal Tumour DNA Sequencing Project, Urachal Cancer Research Fund, Jewish General Hospital Foundation, Ottawa, 2015 - Present

Data Review Committee, Janssen Phase 2 Trial JNJ - 42756493 in Urothelial Cancer, Houston, TX, 2015 - 2020

Panel Member, National Comprehensive Cancer Network (NCCN) - NCCN Clinical Practice Guidelines in Oncology (Bladder Cancer), Fort Washington, PA, 2015 - Present

Panel Member, National Comprehensive Cancer Network (NCCN) - NCCN Clinical Practice Guidelines in Oncology (Penile Cancer), Fort Washington, PA, 2015 - Present

Member, NCI Bladder Cancer Task Force, Washington, 2010 - Present

Alternate Member, NCI Genitourinary Steering Committee, Washington, 2009 - 2014

Institutional Committee Activities

Member, Institutional Faculty Appeals Panel, 2023 - 2027

Quality Officer, Patient Safety Quality, 2019 - 2020

Member, Promotion and Tenure Committee, 2018 - 2021

Member, ICD-10 MedAptus Ambassador, 2012 - 2017

Member, Data Safety Monitoring Board, 2010 - 2015

Member, Clinical Research Committee, 2004 - 2006

Member, Urothelial carcinoma of the Bladder and Upper Tract, Core Development Algorithm, 2004 - Present

Honors & Awards

2025	2025 Castle Connolly Top Doctor, Castle Connolly
2025	Exceptional Women in Medicine, Castle Connolly
2024	Castle Connolly's Exceptional Women in Medicine for 2024, New York Magazine
2021	Ranked "World Expert" top 0.1% of scholars writing about Urinary Bladder Diseases over the past 10 years, ExpertscapeNews
2018	Team Science Award Nomination, MD Anderson
2018	Ranked in the Top 1% by Clinical and Group Consumer Assessment of Healthcare Providers and Systems
2017	Exceptional Women in Medicine, Castle Connolly Medical LTD
2017	America's Top Doctors for Cancer, The American Registry
2017	America's Most Honored Doctors - Top 1%, The American Registry
2017	America's Top Doctors, The American Registry
2015	Nominated for the Gerald P. Bodey Award for Excellence in Education, MDACC
2013	Irwin H. Krakoff Award for Excellence in Clinical Research - Nominee, The University of Texas MD Anderson Cancer Center
2004	The University of Texas M. D. Anderson Cancer Center Bladder SPORE Career Development Award, The University of Texas M. D. Anderson Cancer Center Bladder SPORE
2001	M. D. Anderson Associates Travel Award Winner, M. D. Anderson Associates
2001	ASCO Merit Award, American Society of Clinical Oncology
1992	Michigan State University Outstanding Senior Award, Michigan State University
1992	The John Hopkins Medical and Surgical Association Scholarship
1991	American Heart Association Summer Research Fellow, American Heart Association
1990	The Outstanding Sophomore Woman Engineer
1990	Engineering Summer Research Internship
1988	National Merit Scholar (Finalist)
1988	Gerstacker Scholar

Professional Memberships

European Society for Medical Oncology

2016 - Present

Society of Urologic Oncology

2009 - Present

Southwest Oncology Group Genitourinary Committee

2003 - Present

Southwest Oncology Group

2003 - Present

American Society of Clinical Oncology

2002 - Present

American Association of Cancer Research

2002 - Present

American Urological Association

2002 - Present

Selected Publications

Peer-Reviewed Articles

Moussa, MJ, Tabet, GC, Siefker-Radtke, AO, Xiao, L, Wilson, NR, Gao, J, Logothetis, CJ, Grivas, PD, Lee, B, Shah, AY, Msaouel, P, Li, R, Clemente, LC, Zhao, J, Tannir, NM, Kamat, A, Hansel, DE, Guo, CC, Campbell, M, Alhalabi, O. Histopathologic Progression and Metastatic Relapse Outcomes in Small Cell Neuroendocrine Carcinomas of the Urinary Tract. Cancer medicine 14(2), 2025. e-Pub 2025. PMID: 39831734.
O'Donnell, PH, Loriot, Y, Csoszi, T, Matsubara, N, Shin, SJ, Park, SH, Atduev, V, Gumus, M, Karaca, SB, Grivas, PD, de Wit, R, Castellano, D, Powles, T, Vuky, J, Zhao, Y, O’Hara, K, Okpara, CE, Franco, S, Homet Moreno, B, Zolnierek, J, Siefker-Radtke, AO. Efficacy and safety of pembrolizumab in patients with advanced urothelial carcinoma deemed potentially ineligible for platinum-containing chemotherapy. Cancer 131(1), 2025. e-Pub 2025. PMID: 39465550.
Campbell, M, Shah, AY, Msaouel, P, Tannir, NM, Siefker-Radtke, AO, Kamat, A, Navai, N, Dinney, CP, Rao, P, Guo, CC, Sheth, RA, Venkatesan, AM, Tidwell, RS, Yadav, SS, Gu, A, Chen, H, Macaluso, M, Duan, F, Basu, S, Jindal, S, Sharma, P. A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer. Cancer Research Communications 4(9):2444-2453, 2024. e-Pub 2024. PMID: 39207194.
Msaouel, P, Sweis, R, Bupathi, M, Heath, EI, Goodman, O, Hoimes, C, Milowsky, MI, Davis, NB, Rezazadeh Kalebasty, A, Picus, J, Shaffer, DR, Mao, S, Adra, N, Yorio, J, Gandhi, S, Grivas, PD, Siefker-Radtke, AO, Yang, R, Latven, L, Olson, P, Chin, CD, Der-Torossian, H, Mortazavi, A, Iyer, G. A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma. European Urology Oncology 7(4):933-943, 2024. e-Pub 2024. PMID: 38105142.
Zheng, L, Chen, H, Zhao, J, Roy Chowdhuri, S, Kamat, A, Alhalabi, O, Gao, J, Siefker-Radtke, AO, Hansel, DE, Czerniak, BA, Guo, C. Plasmacytoid urothelial carcinoma of the urinary bladder–A clinicopathological and molecular analysis of 52 cases. Human Pathology 148:1-6, 2024. e-Pub 2024. PMID: 38679207.
Fleming S, Gifkins D, Resnick HE, Shalaby W, Rosenberg P, Gaj C, Maio V, Crawford A, Lu-Yao G, Gao J, Siefker-Radtke A. Prognostic Value of Fibroblast Growth Factor Receptor Genetic Alterations in Metastatic Urothelial Carcinoma. Clin Genitourin Cancer 22(3):102054, 2024. e-Pub 2024. PMID: 38457853.
Necchi, A, Ramlau, RA, Falcón González, A, Chaudhry, A, Todenhöfer, T, Tahbaz, R, Fontana, E, Giannatempo, P, Deville, JL, Pouessel, D, Yoon, S, Powles, T, Bernat, M, Häckl, M, Marszewska, M, McKernan, P, Saulay, M, Scaleia, F, Engelhardt, M, Loriot, Y, Siefker-Radtke, AO, De Santis, M. Derazantinib alone and with atezolizumab in metastatic urothelial carcinoma with activating FGFR aberrations. JNCI Cancer Spectrum 8(3), 2024. e-Pub 2024. PMID: 38627238.
Flaig TW, Spiess PE, Abern M, Agarwal N, Bangs R, Buyyounouski MK, Chan K, Chang SS, Chang P, Friedlander T, Greenberg RE, Guru KA, Herr HW, Hoffman-Censits J, Kaimakliotis H, Kishan AU, Kundu S, Lele SM, Mamtani R, Mian OY, Michalski J, Montgomery JS, Parikh M, Patterson A, Peyton C, Plimack ER, Preston MA, Richards K, Sexton WJ, Siefker-Radtke AO, Stewart T, Sundi D, Tollefson M, Tward J, Wright JL, Cassara CJ, Gurski LA. Bladder Cancer, Version 3.2024. J Natl Compr Canc Netw 22(4):216-225, 2024. e-Pub 2024. PMID: 38754471.
Matsubara N, de Wit R, Balar AV, Siefker-Radtke AO, Zolnierek J, Csoszi T, Shin SJ, Park SH, Atduev V, Gumus M, Su YL, Karaca SB, Cutuli HJ, Sendur MAN, Shen L, O'Hara K, Okpara CE, Franco S, Moreno BH, Grivas P, Loriot Y. Pembrolizumab with or Without Lenvatinib as First-line Therapy for Patients with Advanced Urothelial Carcinoma (LEAP-011): A Phase 3, Randomized, Double-Blind Trial. Eur Urol 85(3):229-238, 2024. e-Pub 2024. PMID: 37778952.
Sood A, Rudzinski JK, Labbate CV, Hensley PJ, Bree KK, Guo CC, Alhalabi O, Campbell MT, Siefker-Radtke AO, Navai N, Dinney CPN, Gao J, Kamat AM. Long-Term Oncological Outcomes in Patients Diagnosed with Non-Metastatic Plasmacytoid Variant of Bladder Cancer: A 20-Year University of Texas MD Anderson Cancer Center Experience. J Urol 211(2):101097JU0000000000003778, 2024. e-Pub 2024. PMID: 37922370.
Siefker-Radtke AO, Matsubara N, Park SH, Huddart RA, Burgess EF, Özgüroglu M, Valderrama BP, Laguerre B, Basso U, Triantos S, Akapame S, Kean Y, Deprince K, Mukhopadhyay S, Loriot Y, Investigators TC. Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial. Ann Oncol 35(1):107-117, 2024. e-Pub 2023. PMID: 37871702.
Alhalabi O, Wilson N, Xiao L, Lin Y, Khandelwal J, Moussa MJ, Msaouel P, Navai N, Gao J, Kamat AM, Pilie P, Shah AY, Goswami S, Matin S, Kovitz C, Holla V, Guo C, Czerniak B, Logothetis C, Corn PG, Dinney CPN, Campbell MT, Hansel DE, Tannir NM, Siefker-Radtke AO. Comparative Effectiveness Analysis of Treatment Strategies for Surgically Resectable Neuroendocrine Carcinoma of the Urinary Tract. Eur Urol Oncol 6(6):611-620, 2023. e-Pub 2023. PMID: 37833193.
Loriot Y, Matsubara N, Park SH, Huddart RA, Burgess EF, Houede N, Banek S, Guadalupi V, Ku JH, Valderrama BP, Tran B, Triantos S, Kean Y, Akapame S, Deprince K, Mukhopadhyay S, Stone NL, Siefker-Radtke AO, Investigators TC. Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma. N Engl J Med 389(21):1961-1971, 2023. e-Pub 2023. PMID: 37870920.
Siefker-Radtke AO, Cauley D, Alhalabi O. Combinations, Sequencing, and the Contribution of Components: New Frontline Standards for Metastatic Urothelial Carcinoma. J Clin Oncol 41(25):JCO2300987, 2023. e-Pub 2023. PMID: 37490639.
Feils AS, Erbe AK, Birstler J, Kim K, Hoch U, Currie SL, Nguyen T, Yu D, Siefker-Radtke AO, Tannir N, Tolaney SM, Diab A, Sondel PM. Associations between KIR/KIR-ligand genotypes and clinical outcome for patients with advanced solid tumors receiving BEMPEG plus nivolumab combination therapy in the PIVOT-02 trial. Cancer Immunol Immunother 72(7):2099-2111, 2023. e-Pub 2023. PMID: 36823323.
Siefker-Radtke, AO. Emerging Therapies in the Treatment of Bladder Cancer. JNCCN Journal of the National Comprehensive Cancer Network 21(55), 2023. e-Pub 2023.
Alhalabi O, Zhu Y, Hamza A, Qiao W, Lin Y, Wang RM, Shah AY, Campbell MT, Holla V, Kamat A, Wang WL, Wang J, Chen J, Meng J, Zhang M, Bondaruk J, Titus M, Genovese G, Czerniak BA, Shaw KR, Meric-Bernstam F, Guo CC, Logothetis CJ, Siefker-Radtke A, Msaouel P, Wang L, Liu J, Gao J. Integrative Clinical and Genomic Characterization of MTAP-deficient Metastatic Urothelial Cancer. Eur Urol Oncol 6(2):228-232, 2023. e-Pub 2023. PMID: 34789422.
Siefker-Radtke AO, Necchi A, Park SH, García-Donas J, Huddart RA, Burgess EF, Fleming MT, Rezazadeh Kalebasty A, Mellado B, Varlamov S, Joshi M, Duran I, Tagawa ST, Zakharia Y, Qi K, Akapame S, Triantos S, O'Hagan A, Loriot Y. Management of Fibroblast Growth Factor Inhibitor Treatment-emergent Adverse Events of Interest in Patients with Locally Advanced or Metastatic Urothelial Carcinoma. Eur Urol Open Sci 50:1-9, 2023. e-Pub 2023. PMID: 37101768.
Rezazadeh Kalebasty A, Benjamin DJ, Loriot Y, Papantoniou D, Siefker-Radtke AO, Necchi A, Naini V, Carcione JC, Santiago-Walker A, Triantos S, Burgess EF. Outcomes of Patients with Advanced Urothelial Carcinoma after Anti-programmed Death-(ligand) 1 Therapy by Fibroblast Growth Factor Receptor Gene Alteration Status: An Observational Study. Eur Urol Open Sci 47:48-57, 2023. e-Pub 2023. PMID: 36601039.
Labbate CV, Hensley PJ, Miest TS, Qiao W, Adibi M, Shah AY, Chery L, Papadopoulos J, Siefker-Radtke AO, Gao J, Guo CC, Czerniak BA, Navai N, Kamat AM, Dinney CP, Campbell MT, Matin SF. Longitudinal GFR trends after neoadjuvant chemotherapy prior to nephroureterectomy for upper tract urothelial carcinoma. Urol Oncol 40(10):454.e17-454.e23, 2022. e-Pub 2022. PMID: 35961847.
Siefker-Radtke AO, Cho DC, Diab A, Sznol M, Bilen MA, Balar AV, Grignani G, Puente E, Tang L, Chien D, Hoch U, Choudhury A, Yu D, Currie SL, Tagliaferri MA, Zalevsky J, Hurwitz ME, Tannir NM. Bempegaldesleukin plus Nivolumab in First-line Metastatic Urothelial Carcinoma: Results from PIVOT-02. Eur Urol 82(4):365-373, 2022. e-Pub 2022. PMID: 35643589.
Zaleski MP, Chen H, Roy-Chowdhuri S, Patel KP, Luthra R, Routbort MJ, Kamat AM, Gao J, Siefker-Radtke A, Czerniak B, Guo CC. Distinct Gene Mutations Are Associated With Clinicopathologic Features in Urachal Carcinoma. Am J Clin Pathol 158(2):263-269, 2022. e-Pub 2022. PMID: 35467000.
Flaig TW, Spiess PE, Abern M, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Chan K, Chang S, Friedlander T, Greenberg RE, Guru KA, Herr HW, Hoffman-Censits J, Kishan A, Kundu S, Lele SM, Mamtani R, Margulis V, Mian OY, Michalski J, Montgomery JS, Nandagopal L, Pagliaro LC, Parikh M, Patterson A, Plimack ER, Pohar KS, Preston MA, Richards K, Sexton WJ, Siefker-Radtke AO, Tollefson M, Tward J, Wright JL, Dwyer MA, Cassara CJ, Gurski LA. NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022. J Natl Compr Canc Netw 20(8):866-878, 2022. e-Pub 2022. PMID: 35948037.
Siefker-Radtke AO, Loriot Y. Erdafitinib for locally advanced or metastatic urothelial carcinoma. Am J Health Syst Pharm 79(11):824-825, 2022. e-Pub 2022. PMID: 35147178.
Alhalabi O, Chen J, Zhang Y, Lu Y, Wang Q, Ramachandran S, Tidwell RS, Han G, Yan X, Meng J, Wang R, Hoang AG, Wang WL, Song J, Lopez L, Andreev-Drakhlin A, Siefker-Radtke A, Zhang X, Benedict WF, Shah AY, Wang J, Msaouel P, Zhang M, Guo CC, Czerniak B, Behrens C, Soto L, Papadimitrakopoulou V, Lewis J, Rinsurongkawong W, Rinsurongkawong V, Lee J, Roth J, Swisher S, Wistuba I, Heymach J, Wang J, Campbell MT, Efstathiou E, Titus M, Logothetis CJ, Ho TH, Zhang J, Wang L, Gao J. MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers. Nat Commun 13(1):1797, 2022. e-Pub 2022. PMID: 35379845.
Tannir NM, Cho DC, Diab A, Sznol M, Bilen MA, Balar AV, Grignani G, Puente E, Tang L, Chien D, Hoch U, Choudhury A, Yu D, Currie SL, Tagliaferri MA, Zalevsky J, Siefker-Radtke AO, Hurwitz ME. Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study. J Immunother Cancer 10(4), 2022. e-Pub 2022. PMID: 35444058.
Adibi M, McCormick B, Economides MP, Petros F, Xiao L, Guo C, Shah A, Kamat AM, Dinney C, Navai N, Gao J, Siefker-Radtke A, Matin SF, Campbell MT. Five and Ten-Year Outcomes of Neoadjuvant Chemotherapy and Surgery for High-Risk Upper Tract Urothelial Carcinoma. Clin Genitourin Cancer 20(2):176-182, 2022. e-Pub 2022. PMID: 35039231.
Alhalabi O, Hahn AW, Msaouel P, Meric-Bernstam F, Wilson N, Naing A, Piha-Paul S, Janku F, Pant S, Yap TA, Hong DS, Fu S, Karp D, Beltran K, Campbell E, Le H, Campbell MT, Shah A, Tannir NM, Siefker-Radtke A, Gao J, Roszik J, Subbiah V. Validation of Prognostic Scores in Patients With Metastatic Urothelial Cancer Enrolling in Phase I Targeted Therapy or Next Generation Immunotherapy Trials. Clin Genitourin Cancer 20(1):e16-e24, 2022. e-Pub 2022. PMID: 34362693.
Siefker-Radtke AO, Necchi A, Park SH, García-Donas J, Huddart RA, Burgess EF, Fleming MT, Rezazadeh Kalebasty A, Mellado B, Varlamov S, Joshi M, Duran I, Tagawa ST, Zakharia Y, Akapame S, Santiago-Walker AE, Monga M, O'Hagan A, Loriot Y, Group BLC. Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study. Lancet Oncol 23(2):248-258, 2022. e-Pub 2022. PMID: 35030333.
Alhalabi, O, Campbell, M, Xiao, L, Adriazola, AC, Wilson, NR, Siefker-Radtke, AO, Corn, P, Zurita-Saavedra, A, Jonasch, E, Gao, J, Adibi, M, Kamat, A, Navai, N, Pisters, LL, Dinney, CP, Matin, S, Shah, AY. Multimodal kidney-preserving approach in localised and locally advanced high-risk upper tract urothelial carcinoma. BJUI Compass 3(1):37-44, 2022. e-Pub 2022. PMID: 35475152.
Hensley PJ, Bree KK, Campbell MT, Alhalabi O, Kokorovic A, Miest T, Nogueras-Gonzalez GM, Gao J, Siefker-Radtke AO, Guo CC, Navai N, Dinney CP, Kamat AM. Reply by Authors. J Urol 206(5):101097JU000000000000194302, 2021. e-Pub 2021. PMID: 34372685.
Hensley PJ, Bree KK, Campbell MT, Alhalabi O, Kokorovic A, Miest T, Nogueras-Gonzalez GM, Gao J, Siefker-Radtke AO, Guo CC, Navai N, Dinney CP, Kamat AM. Progression of Disease after BCG Therapy: Refining Patient Selection for Neoadjuvant Chemotherapy before Radical Cystectomy. J Urol 206(5):101097JU0000000000001943, 2021. e-Pub 2021. PMID: 34184926.
Alhalabi, Omar, Campbell, Matthew T, Xiao, Lianchun, Adriazola, Ana C, Wilson, Nathaniel R, Siefker-Radtke, Arlene O, Corn, Paul G, Zurita, Amado, Jonasch, Eric, Gao, Jianjun, Adibi, Mehrad, Kamat, Ashish M, Navai, Neema, Pisters, Louis L, Dinney, Colin, Matin, Surena F, Shah, Amishi Y. Multimodal kidney-preserving approach in localised and locally advanced high-risk upper tract urothelial carcinoma. BJUI Compass, 2021. e-Pub 2021.
Han G, Yang G, Hao D, Lu Y, Thein K, Simpson BS, Chen J, Sun R, Alhalabi O, Wang R, Dang M, Dai E, Zhang S, Nie F, Zhao S, Guo C, Hamza A, Czerniak B, Cheng C, Siefker-Radtke A, Bhat K, Futreal A, Peng G, Wargo J, Peng W, Kadara H, Ajani J, Swanton C, Litchfield K, Ahnert JR, Gao J, Wang L. 9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy. Nat Commun 12(1):5606, 2021. e-Pub 2021. PMID: 34556668.
Msaouel P, Oromendia C, Siefker-Radtke AO, Tannir NM, Subudhi SK, Gao J, Wang Y, Siddiqui BA, Shah AY, Aparicio AM, Campbell MT, Zurita AJ, Shaw LK, Lopez LP, McCord H, Chakraborty SN, Perales J, Lu C, Van Alstine ML, Elashoff M, Logothetis C. Evaluation of Technology-Enabled Monitoring of Patient-Reported Outcomes to Detect and Treat Toxic Effects Linked to Immune Checkpoint Inhibitors. JAMA Netw Open 4(8):e2122998, 2021. e-Pub 2021. PMID: 34459906.
Galsky MD, Hoimes CJ, Necchi A, Shore N, Witjes JA, Steinberg G, Bedke J, Nishiyama H, Fang X, Kataria R, Sbar E, Jia X, Siefker-Radtke A. Perioperative pembrolizumab therapy in muscle-invasive bladder cancer: Phase III KEYNOTE-866 and KEYNOTE-905/EV-303. Future Oncol 17(24):3137-3150, 2021. e-Pub 2021. PMID: 34008425.
Siddiqui BA, Gheeya JS, Goswamy R, Bathala TK, Surasi DS, Gao J, Shah A, Campbell MT, Msaouel P, Goswami S, Wang J, Zurita AJ, Jonasch E, Corn PG, Aparicio AM, Siefker-Radtke AO, Sharma P, Subudhi SK, Tannir N. Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events. J Immunother Cancer 9(7), 2021. e-Pub 2021. PMID: 34326169.
Knowles M, Dyrskjøt L, Heath EI, Bellmunt J, Siefker-Radtke AO. Metastatic urothelial carcinoma. Cancer Cell 39(5):583-585, 2021. e-Pub 2021. PMID: 33974855.
Siefker-Radtke, AO. New settings for immune checkpoint inhibitors in urothelial cancer. JNCCN Journal of the National Comprehensive Cancer Network 19:629-632, 2021. e-Pub 2021.
McGregor BA, Campbell MT, Xie W, Farah S, Bilen MA, Schmidt AL, Sonpavde GP, Kilbridge KL, Choudhury AD, Mortazavi A, Shah AY, Venkatesan AM, Bubley GJ, Siefker-Radtke AO, McKay RR, Choueiri TK. Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies. Cancer 127(6):840-849, 2021. e-Pub 2021. PMID: 33216356.
Alhalabi O, Hahn AW, Msaouel P, Andreev-Drakhlin AY, Meric-Bernstam F, Naing A, Piha-Paul S, Filip J, Pant S, Yap TA, Hong DS, Fu S, Karp D, Campbell E, Le H, Campbell MT, Shah AY, Tannir NM, Siefker-Radtke AO, Gao J, Roszik J, Subbiah V. Molecular profiling of metastatic bladder cancer early-phase clinical trial participants predicts patient outcomes. Mol Cancer Res 19(3):395-402, 2021. e-Pub 2021. PMID: 33323389.
Huddart RA, Siefker-Radtke AO, Balar AV, Bilen MA, Powles T, Bamias A, Castellano D, Khalil MF, Van Der Heijden MS, Koshkin VS, Pook DW, Özgüroglu M, Santiago L, Zhong B, Chien D, Lin W, Tagliaferri MA, Loriot Y. PIVOT-10: Phase II study of bempegaldesleukin plus nivolumab in cisplatin-ineligible advanced urothelial cancer. Future Oncol 17(2):137-149, 2021. e-Pub 2021. PMID: 32938232.
Gao J, Navai N, Alhalabi O, Siefker-Radtke A, Campbell MT, Tidwell RS, Guo CC, Kamat AM, Matin SF, Araujo JC, Shah AY, Msaouel P, Corn P, Wang J, Papadopoulos JN, Yadav SS, Blando JM, Duan F, Basu S, Liu W, Shen Y, Zhang Y, Macaluso MD, Wang Y, Chen J, Zhang J, Futreal A, Dinney C, Allison JP, Goswami S, Sharma P. Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. Nat Med. e-Pub 2020. PMID: 33046869.
Yang G, Bondaruk J, Cogdell D, Wang Z, Lee S, Lee JG, Zhang S, Choi W, Wang Y, Liang Y, Wang G, Wang Y, Yao H, Dadhania V, Gao J, Logothetis C, Siefker-Radtke A, Kamat A, Dinney C, Theodorescu D, Kimmel M, Wei P, Guo CC, Weinstein JN, McConkey DJ, Czerniak B. Urothelial-to-Neural Plasticity Drives Progression to Small Cell Bladder Cancer. iScience 23(6):101201, 2020. e-Pub 2020. PMID: 32521509.
Galsky MD, Saci A, Szabo PM, Han GC, Grossfeld G, Collette S, Siefker-Radtke A, Necchi A, Sharma P. Nivolumab in Patients with Advanced Platinum-Resistant Urothelial Carcinoma: Efficacy, Safety, and Biomarker Analyses with Extended Follow-up from CheckMate 275. Clin Cancer Res. e-Pub 2020. PMID: 32532789.
Alhalabi O, Campbell M, Shah A, Siefker-Radtke A, Gao J. Emerging treatments in advanced urothelial cancer. Curr Opin Oncol 32(3):232-239, 2020. e-Pub 2020. PMID: 32209822.
Schmidt AL, Siefker-Radtke A, McConkey D, McGregor B. Renal Cell and Urothelial Carcinoma: Biomarkers for New Treatments. Am Soc Clin Oncol Educ Book 40:1-11, 2020. e-Pub 2020. PMID: 32379987.
Flaig TW, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Chang S, Downs TM, Efstathiou JA, Friedlander T, Greenberg RE, Guru KA, Guzzo T, Herr HW, Hoffman-Censits J, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Michalski J, Montgomery JS, Nandagopal L, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Preston MA, Sexton WJ, Siefker-Radtke AO, Tward J, Wright JL, Gurski LA, Johnson-Chilla A. Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 18(3):329-354, 2020. e-Pub 2020. PMID: 32135513.
Kamoun A, de Reyniès A, Allory Y, Sjödahl G, Robertson AG, Seiler R, Hoadley KA, Groeneveld CS, Al-Ahmadie H, Choi W, Castro MAA, Fontugne J, Eriksson P, Mo Q, Kardos J, Zlotta A, Hartmann A, Dinney CP, Bellmunt J, Powles T, Malats N, Chan KS, Kim WY, McConkey DJ, Black PC, Dyrskjøt L, Höglund M, Lerner SP, Real FX, Radvanyi F, Aine M, Bernard-Pierrot I, Czerniak B, Gibb EA, Kim J, Kwiatkowski DJ, Lebret T, Liedberg F, Siefker-Radtke AA, Sirab N, Taber A, Weinstein JN. Reply To Kenneth B. Yatai, Mark J. Dunning, Dennis Wang. Consensus Genomic Subtypes of Muscle-invasive Bladder Cancer: A Step in the Right Direction but Still a Long Way To Go. Eur Urol. In press. Eur Urol. e-Pub 2020. PMID: 32037144.
Wang L, Gong Y, Saci A, Szabo PM, Martini A, Necchi A, Siefker-Radtke A, Pal S, Plimack ER, Sfakianos JP, Bhardwaj N, Horowitz A, Farkas AM, Mulholland D, Fischer BS, Oh WK, Sharma P, Zhu J, Galsky MD. Fibroblast Growth Factor Receptor 3 Alterations and Response to PD-1/PD-L1 Blockade in Patients with Metastatic Urothelial Cancer. Eur Urol 76(5):599-603, 2019. e-Pub 2019. PMID: 31272788.
Loriot Y, Necchi A, Siefker-Radtke AO. Erdafitinib in Urothelial Carcinoma. Reply. N Engl J Med 381(16):1594-1595, 2019. e-Pub 2019. PMID: 31618553.
Loriot Y, Necchi A, Park SH, Garcia-Donas J, Huddart R, Burgess E, Fleming M, Rezazadeh A, Mellado B, Varlamov S, Joshi M, Duran I, Tagawa ST, Zakharia Y, Zhong B, Stuyckens K, Santiago-Walker A, De Porre P, O'Hagan A, Avadhani A, Siefker-Radtke AO, Group BLC. Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. N Engl J Med 381(4):338-348, 2019. e-Pub 2019. PMID: 31340094.
Ohyama C, Kojima T, Kondo T, Naya Y, Inoue T, Tomita Y, Eto M, Hisasue S, Uemura H, Obara W, Kikuchi E, Sharma P, Galsky MD, Siefker-Radtke A, Grossfeld G, Collette S, Gooden K, Kimura G. Nivolumab in patients with unresectable locally advanced or metastatic urothelial carcinoma: CheckMate 275 2-year global and Japanese patient population analyses. Int J Clin Oncol. e-Pub 2019. PMID: 31218529.
Duplisea JJ, Petros FG, Li R, Fellman B, Guo CC, Czerniak BA, Siefker-Radtke AO, Araujo JC, Dinney CPN, Matin SF. Outcomes of nonmetastatic micropapillary variant upper tract urothelial carcinoma. Urol Oncol 37(6):354.e19-354.e26, 2019. e-Pub 2019. PMID: 30777393.
Sharma P, Siefker-Radtke A, de Braud F, Basso U, Calvo E, Bono P, Morse MA, Ascierto PA, Lopez-Martin J, Brossart P, Rohrberg K, Mellado B, Fischer BS, Meadows-Shropshire S, Saci A, Callahan MK, Rosenberg J. Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results. J Clin Oncol:JCO1900538. e-Pub 2019. PMID: 31100038.
Alhalabi O, Rafei H, Shah A, Siefker-Radtke A, Campbell M, Gao J. Targeting advanced urothelial carcinoma-developing strategies. Curr Opin Oncol 31(3):207-215, 2019. e-Pub 2019. PMID: 30844889.
Merseburger AS, Apolo AB, Chowdhury S, Hahn NM, Galsky MD, Milowsky MI, Petrylak D, Powles T, Quinn DI, Rosenberg JE, Siefker-Radtke A, Sonpavde G, Sternberg CN. SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancer. World J Urol 37(1):95-105, 2019. e-Pub 2019. PMID: 30238401.
Wang G, Xiao L, Zhang M, Kamat AM, Siefker-Radtke AO, Dinney CP, Czerniak B, Guo CC. Small cell carcinoma of the urinary bladder: a Clinicopathologic and Immunohistochemical analysis of 81 cases. Hum Pathol 79:57-65, 2018. e-Pub 2018. PMID: 29763719.
Flaig TW, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Downs TM, Efstathiou JA, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Petrylak DP, Plimack ER, Pohar KS, Porter MP, Preston MA, Sexton WJ, Siefker-Radtke AO, Tward J, Wile G, Johnson-Chilla A, Dwyer MA, Gurski LA. NCCN Guidelines Insights: Bladder Cancer, Version 5.2018. J Natl Compr Canc Netw 16(9):1041-1053, 2018. e-Pub 2018. PMID: 30181416.
Wang L, Saci A, Szabo PM, Chasalow SD, Castillo-Martin M, Domingo-Domenech J, Siefker-Radtke AO, Sharma P, Sfakianos JP, Gong Y, Dominguez-Andres A, Oh WK, Mulholland D, Azrilevich A, Hu L, Cordon-Cardo C, Salmon H, Bhardwaj N, Zhu J, Galsky MD. EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer. Nat Commun 9(1):3503, 2018. e-Pub 2018. PMID: 30158554.
Mmeje CO, Benson CR, Nogueras-González GM, Jayaratna IS, Gao J, Siefker-Radtke AO, Kamat AM, Dinney CP, Navai N, Shah JB. Determining the optimal time for radical cystectomy after neoadjuvant chemotherapy. BJU Int 122(1):89-98, 2018. e-Pub 2018. PMID: 29569824.
Metcalfe MJ, Ferguson JE, Li R, Xiao L, Guo CC, Czerniak BA, Siefker-Radtke AO, Pretzsch SM, Navai N, McConkey DJ, Kamat AM, Campbell M, Dinney C. Impact of High-risk Features and Effect of Neoadjuvant Chemotherapy in Urothelial Cancer Patients with Invasion into the Lamina Propria on Transurethral Resection in the Absence of Deep Muscle Invasion. Eur Urol Focus 3(6):577-583, 2017. e-Pub 2017. PMID: 28753816.
Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Clark PE, Downs TM, Efstathiou JA, Flaig TW, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Preston MA, Sexton WJ, Siefker-Radtke AO, Sonpavde G, Tward J, Wile G, Dwyer MA, Gurski LA. Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 15(10):1240-1267, 2017. e-Pub 2017. PMID: 28982750.
Wang G, Huang H, Kamat AM, Siefker-Radtke AO, Dinney CP, Troncoso P, Czerniak B, Guo CC. High-grade neuroendocrine carcinoma of the urachus-report of 3 cases. Hum Pathol 67:126-133, 2017. e-Pub 2017. PMID: 28823575.
Fernández MI, Williams SB, Willis DL, Slack RS, Dickstein RJ, Parikh S, Chiong E, Siefker-Radtke AO, Guo CC, Czerniak BA, McConkey DJ, Shah JB, Pisters LL, Grossman HB, Dinney CP, Kamat AM. Clinical risk stratification in patients with surgically resectable micropapillary bladder cancer. BJU Int 119(5):684-691, 2017. e-Pub 2017. PMID: 27753185.
Fox MD, Xiao L, Zhang M, Kamat AM, Siefker-Radtke AO, Zhang L, Dinney CP, Czerniak B, Guo CC. Plasmacytoid Urothelial Carcinoma of the Urinary Bladder: A Clinicopathologic and Immunohistochemical Analysis of 49 Cases. Am J Clin Pathol 147(5):500-506, 2017. e-Pub 2017. PMID: 28371875.
Sharma P, Retz M, Siefker-Radtke AO, Baron A, Necchi A, Bedke J, Plimack ER, Vaena D, Grimm MO, Bracarda S, JÁ A, Pal S, Ohyama C, Saci A, Qu X, Lambert A, Krishnan S, Azrilevich A, Galsky MD. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol 18(3):312-322, 2017. e-Pub 2017. PMID: 28131785.
Gakis G, Schubert T, Alemozaffar M, Bellmunt J, Bochner BH, Boorjian SA, Daneshmand S, Huang WC, Kondo T, Konety BR, Laguna MP, Matin SF, Siefker-Radtke AO, Shariat SF, Stenzl A. Update of the ICUD-SIU consultation on upper tract urothelial carcinoma 2016: treatment of localized high-risk disease. World J Urol 35(3):327-335, 2017. e-Pub 2017. PMID: 27043218.
Pham MN, Apolo AB, De Santis M, Galsky MD, Leibovich BC, Pisters LL, Siefker-Radtke AO, Sonpavde G, Steinberg GD, Sternberg CN, Tagawa ST, Weizer AZ, Woods ME, Milowsky MI. Upper tract urothelial carcinoma topical issue 2016: treatment of metastatic cancer. World J Urol 35(3):367-378, 2017. e-Pub 2017. PMID: 27342991.
Ochoa AE, Choi W, Su X, Siefker-Radtke AO, Czerniak B, Dinney C, McConkey DJ. Specific micro-RNA expression patterns distinguish the basal and luminal subtypes of muscle-invasive bladder cancer. Oncotarget. e-Pub 2016. PMID: 27845906.
Kim C, Gao J, Shannon VR, Siefker-Radtke A. Systemic sarcoidosis first manifesting in a tattoo in the setting of immune checkpoint inhibition. BMJ Case Rep 2016, 2016. e-Pub 2016. PMID: 27797838.
Clark PE, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Efstathiou JA, Flaig TW, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Kader AK, Kibel AS, Kuzel TM, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Petrylak D, Plimack ER, Pohar KS, Porter MP, Sexton WJ, Siefker-Radtke AO, Sonpavde G, Tward J, Wile G, Dwyer MA, Smith C. NCCN Guidelines Insights: Bladder Cancer, Version 2.2016. J Natl Compr Canc Netw 14(10):1213-1224, 2016. e-Pub 2016. PMID: 27697976.
Dadhania V, Zhang M, Zhang L, Bondaruk J, Majewski T, Siefker-Radtke AO, Guo CC, Dinney C, Cogdell DE, Zhang S, Lee S, Lee JG, Weinstein JN, Baggerly K, McConkey D, Czerniak B. Meta-Analysis of the Luminal and Basal Subtypes of Bladder Cancer and the Identification of Signature Immunohistochemical Markers for Clinical Use. EBioMedicine 12:105-117, 2016. e-Pub 2016. PMID: 27612592.
Pal SK, Agarwal N, Boorjian SA, Hahn NM, Siefker-Radtke AO, Clark PE, Plimack ER. National Comprehensive Cancer Network Recommendations on Molecular Profiling of Advanced Bladder Cancer. J Clin Oncol 34(27):3346-8, 2016. e-Pub 2016. PMID: 27458279.
Siefker-Radtke AO, Zhang XQ, Guo CC, Shen Y, Pirollo KF, Sabir S, Leung C, Leong-Wu C, Ling CM, Chang EH, Millikan RE, Benedict WF. A Phase l Study of a Tumor-targeted Systemic Nanodelivery System, SGT-94, in Genitourinary Cancers. Mol Ther. e-Pub 2016. PMID: 27480598.
McConkey DJ, Choi W, Shen Y, Lee IL, Porten S, Matin SF, Kamat AM, Corn P, Millikan RE, Dinney C, Czerniak B, Siefker-Radtke AO. A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naïve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer. Eur Urol 69(5):855-862, 2016. e-Pub 2016. PMID: 26343003.
Campbell MT, Siefker-Radtke AO, Gao J. The State of Immune Checkpoint Inhibition in Urothelial Carcinoma: Current Evidence and Future Areas of Exploration. Cancer J 22(2):96-100, 2016. e-Pub 2016. PMID: 27111904.
Guo CC, Dadhania V, Zhang L, Majewski T, Bondaruk J, Sykulski M, Wronowska W, Gambin A, Wang Y, Zhang S, Fuentes-Mattei E, Kamat AM, Dinney C, Siefker-Radtke AO, Choi W, Baggerly KA, McConkey D, Weinstein J, Czerniak B. Gene Expression Profile of the Clinically Aggressive Micropapillary Variant of Bladder Cancer. Eur Urol. e-Pub 2016. PMID: 26988609.
Siefker-Radtke AO, Campbell MT, Munsell MF, Harris DR, Carolla RL, Pagliaro LC. Front-line treatment with gemcitabine, paclitaxel and doxorubicin for patients with unresectable or metastatic urothelial cancer and poor renal function: Final results from a phase II study. Urology 89:83-9, 2016. e-Pub 2016. PMID: 26723185.
Ho PL, Willis DL, Patil J, Xiao L, Williams SB, Melquist JJ, Tart K, Parikh S, Shah JB, Delacroix SE, Navai N, Siefker-Radtke AO, Dinney CP, Pisters LL, Kamat AM. Outcome of patients with clinically node positive bladder cancer undergoing consolidative surgery after preoperative chemotherapy: The M.D. Anderson Cancer Center experience. Urol Oncol 34(2):59.e1-8, 2016. e-Pub 2016. PMID: 26421586.
Dhillon J, Liang Y, Kamat AM, Siefker-Radtke AO, Dinney CP, Czerniak B, Guo CC. Urachal carcinoma: a pathologic and clinical study of 46 cases. Hum Pathol 46(12):1808-14, 2015. e-Pub 2015. PMID: 26364859.
Campbell MT, Millikan RE, Altinmakas E, Xiao L, Wen SJ, Siefker-Radtke AO, Aparicio A, Corn PG, Tannir NM. Phase I Trial of Sunitinib and Temsirolimus in Metastatic Renal Cell Carcinoma. Clin Genitourin Cancer 13(3):218-24, 2015. e-Pub 2015. PMID: 25465491.
Fernandez MI, Williams SB, Willis DL, Slack RS, Dickstein R, Parikh S, Siefker-Radtke AO, Guo CC, Czerniak BA, Shah JB, Pisters LL, Grossman HB, Dinney CP, Kamat AM. MP72-02 Outcome of Patients with Micropapillary Bladder Cancer Treated with Radical Cystectomy With/Without Neoadjuvant Chemotherapy. The Journal of Urology 193(4):e921, 2015. e-Pub 2015.
Mmeje C, Benson C, Nogueras-Gonzalez G, Jayaratna I, Navai N, Gao J, SieferRadtke A, Kamat A, Dinney C, Shah J. MP65-05 Determining the Optimal Timing for Radical Cystectomy After Neoadjuvant Chemotherapy. The Journal of Urology 193(4):e808-e809, 2015. e-Pub 2015.
Hussain M, Daignault S, Agarwal N, Grivas PD, Siefker-Radtke AO, Puzanov I, MacVicar GR, Levine EG, Srinivas S, Twardowski P, Eisenberger MA, Quinn DI, Vaishampayan UN, Yu EY, Dawsey S, Day KC, Day ML, Al-Hawary M, Smith DC. A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma. Cancer 120(17):2684-93, 2014. e-Pub 2014. PMID: 24802654.
Choi W, Czerniak B, Ochoa A, Su X, Siefker-Radtke AO, Dinney C, McConkey DJ. Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer. Nat Rev Urol 11(7):400-410, 2014. e-Pub 2014. PMID: 24960601.
Porten S, Siefker-Radtke AO, Xiao L, Margulis V, Kamat AM, Wood CG, Jonasch E, Dinney CP, Matin SF. Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma. Cancer 120(12):1794-9, 2014. e-Pub 2014. PMID: 24633966.
Choi W, Porten S, Kim S, Willis D, Plimack ER, Hoffman-Censits J, Roth B, Cheng T, Tran M, Lee IL, Melquist J, Bondaruk J, Majewski T, Zhang S, Pretzsch S, Baggerly K, Siefker-Radtke AO, Czerniak B, Dinney CP, McConkey DJ. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 25(2):152-65, 2014. e-Pub 2014. PMID: 24525232.
Culp SH, Dickstein RJ, Grossman HB, Pretzsch SM, Porten S, Daneshmand S, Cai J, Groshen S, Siefker-Radtke AO, Millikan RE, Czerniak B, Navai N, Wszolek MF, Kamat AM, Dinney CP. Refining Patient Selection for Neoadjuvant Chemotherapy Prior to Radical Cystectomy. J Urol 191(1):40-7, 2014. e-Pub 2014. PMID: 23911605.
Solomon DA, Kim JS, Bondaruk J, Shariat SF, Wang ZF, Elkahloun AG, Ozawa T, Gerard J, Zhuang D, Zhang S, Navai N, Siefker-Radtke AO, Phillips JJ, Robinson BD, Rubin MA, Volkmer B, Hautmann R, Küfer R, Hogendoorn PC, Netto G, Theodorescu D, James CD, Czerniak B, Miettinen M, Waldman T. Frequent truncating mutations of STAG2 in bladder cancer. Nat Genet 45(12):1428-30, 2013. e-Pub 2013. PMID: 24121789.
Lynch SP, Shen Y, Kamat A, Grossman HB, Shah JB, Millikan RE, Dinney CP, Siefker-Radtke A. Neoadjuvant chemotherapy in small cell urothelial cancer improves pathologic down-staging and long-term outcomes. Results from a retrospective study at the M.D. Anderson Cancer Center. Eur Urol 64(2):307-13, 2013. e-Pub 2013. PMID: 22564397.
Galsky MD, Hendricks R, Svatek R, Bangs R, Hoffman-Censits J, Clement J, Dreicer R, Guancial E, Hahn N, Lerner SP, O'Donnell PH, Quale DZ, Siefker-Radtke AO, Shipley W, Sonpavde G, Vaena D, Vinson J, Rosenberg J. Critical analysis of contemporary clinical research in muscle-invasive and metastatic urothelial cancer: A report from the Bladder Cancer Advocacy Network Clinical Trials Working Group. Cancer 119(11):1994-8, 2013. e-Pub 2013. PMID: 23456777.
Dayyani F, Czerniak BA, Sircar K, Munsell MF, Millikan RE, Dinney CP, Siefker-Radtke AO. Plasmacytoid Urothelial Carcinomas - A Chemo-sensitive Cancer with Poor Prognosis, and Peritoneal Carcinomatosis. J Urol 189(5):1659 - 1661, 2013. e-Pub 2013. PMID: 23159581.
Siefker-Radtke AO, Dinney CP, Shen Y, Williams DL, Kamat AM, Grossman HB, Millikan RE. A Phase 2 Clinical Trial of Sequential Neoadjuvant Chemotherapy With Ifosfamide, Doxorubicin, and Gemcitabine Followed by Cisplatin, Gemcitabine, and Ifosfamide in Locally Advanced Urothelial Cancer. Cancer 119(3):540-7, 2013. e-Pub 2013. PMID: 22914978.
Tran MN, Choi W, Wszolek MF, Navai N, Lee IL, Nitti G, Wen S, Flores ER, Siefker-Radtke AO, Czerniak B, Dinney C, Barton M, McConkey DJ. The p63 isoform ΔNp63α inhibits epithelial-mesenchymal transition in human bladder cancer cells: Role of miR205. J Biol Chem 288(5):3275-3288, 2013. e-Pub 2013. PMID: 23239884.
Qi W, White MC, Choi W, Guo C, Dinney C, McConkey DJ, Siefker-Radtke A. Inhibition of inducible heat shock protein-70 (hsp72) enhances bortezomib-induced cell death in human bladder cancer cells. PLoS One 8(7):e69509, 2013. e-Pub 2013. PMID: 23874968.
Rodney AJ, Tannir NM, Siefker-Radtke AO, Liu P, Walsh GL, Millikan RE, Swisher SG, Tu SM, Pagliaro LC. Survival outcomes for men with mediastinal germ-cell tumors: The University of Texas MD Anderson Cancer Center experience. Urol Oncol 30(6):879-85, 2012. e-Pub 2012. PMID: 20933444.
Marquis L, Tran M, Choi W, Lee IL, Huszar D, Siefker-Radtke AO, Dinney C, McConkey DJ. p63 expression correlates with sensitivity to the Eg5 inhibitor ZD4877 in bladder cancer cells. Cancer Biol Ther 13(7):477- 486, 2012. e-Pub 2012. PMID: 22361733.
Alva AS, Matin SF, Lerner SP, Siefker-Radtke AO. Perioperative chemotherapy for upper tract urothelial cancer. Nat Rev Urol 9(5):266 - 273, 2012. e-Pub 2012. PMID: 22487872.
Choi W, Shah JB, Tran M, Svatek R, Marquis L, Lee IL, Yu D, Adam L, Wen S, Shen Y, Dinney C, McConkey DJ, Siefker-Radtke A. p63 expression defines a lethal subset of muscle-invasive bladder cancers. PLoS One 7(1):e30206, 2012. e-Pub 2012. PMID: 22253920.
Rajput MZ, Kamat AM, Clavell-Hernandez J, Siefker-Radtke AO, Grossman HB, Dinney CP, Matin SF. Perioperative outcomes of laparoscopic radical nephroureterectomy and regional lymphadenectomy in patients with upper urinary tract urothelial carcinoma after neoadjuvant chemotherapy. Urology 78(1):61-7, 2011. e-Pub 2011. PMID: 21354598.
Black PC, Dinney CP, Brown GA, Kassouf W, Siefker-Radtke AO, Munsell MF, Grossman HB, Kamat AM. The role of radical cystectomy in patients with clinical T4b bladder cancer. Urol Oncol 29(2):157-161, 2011. e-Pub 2011. PMID: 20456984.
Svatek RS, Shariat SF, Lasky RE, Skinner EC, Novara G, Lerner SP, Fradet Y, Bastian PJ, Kassouf W, Karakiewicz PI, Fritsche HM, Müller SC, Izawa JI, Ficarra V, Sagalowsky AI, Schoenberg MP, Siefker-Radtke AO, Millikan RE, Dinney CP. The effectiveness of off-protocol adjuvant chemotherapy for patients with urothelial carcinoma of the urinary bladder. Clin Cancer Res 16(17):4461-7, 2010. e-Pub 2010. PMID: 20651056.
Matin SF, Margulis V, Kamat A, Wood CG, Grossman HB, Brown GA, Dinney CP, Millikan R, Siefker-Radtke AO. Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high-risk upper tract transitional cell carcinoma. Cancer 116(13):3127-34, 2010. e-Pub 2010. PMID: 20564621.
McConkey DJ, Lee S, Choi W, Tran M, Majewski T, Lee S, Siefker-Radtke AO, Dinney C, Czerniak B. Molecular genetics of bladder cancer: Emerging mechanisms. Urol Oncol 28(4):429-40, 2010. e-Pub 2010. PMID: 20610280.
Siefker-Radtke A. Bladder cancer: can we move beyond chemotherapy?. Curr Oncol Rep 12(4):278-83, 2010. e-Pub 2010. PMID: 20446067.
Childs MA, Wood CG, Spiess, PE, Debiane L, Hernandez M, Matin S, Millikan R, Siefker-Radtke AO, Scott SM, Pisters LL. Early results of chemotherapy with retroperitoneal lymph node dissection for isolated retroperitoneal recurrence of upper urinary tract urothelial carcinoma after nephroureterectomy. The Canadian Journal of Urology 17(3):5184-5189, 2010. e-Pub 2010.
Logothetis CJ, Siefker-Radtke A. Words of wisdom. Re: final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium. Eur Urol 57(4):728-9, 2010. e-Pub 2010. PMID: 20965043.
Hussain MH, Wood DP, Bajorin DF, Bochner BH, Dreicer R, Lamm DL, O'Donnell MA, Siefker-Radtke AO, Theodorescu D, Dinney CP. Bladder cancer: narrowing the gap between evidence and practice. J Clin Oncol 27(34):5680-4, 2009. e-Pub 2009. PMID: 19858384.
McConkey DJ, Choi W, Marquis L, Martin F, Williams MB, Shah J, Svatek R, Das A, Adam L, Kamat A, Siefker-Radtke AO, Dinney C. Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer. Cancer Metastasis Rev 28(3-4):335-44, 2009. e-Pub 2009. PMID: 20012924.
Svatek RS, Siefker-Radtke AO, Dinney CP. Management of metastatic urothelial cancer: the role of surgery as an adjunct to chemotherapy. Can Urol Assoc J 3(6 Suppl 4):S228-31, 2009. e-Pub 2009. PMID: 20019991.
Adam L, Zhong M, Choi W, Qi W, Nicoloso M, Arora A, Calin G, Wang H, Siefker-Radtke AO, McConkey D, Bar-Eli M, Dinney C. miR-200 expression regulates epithelial to mesenchymal transition in bladder cancer cells and reverses resistance to EGFR therapy. Clin Cancer Res 15(16):5060-72, 2009. e-Pub 2009. PMID: 19671845.
Siefker-Radtke AO, Kamat AM, Grossman HB, Williams DL, Qiao W, Thall PF, Dinney CP, Millikan RE. Phase II clinical trial of neoadjuvant alternating doublet chemotherapy with ifosfamide/doxorubicin and etoposide/cisplatin in small-cell urothelial cancer. J Clin Oncol 27(16):2592-7, 2009. e-Pub 2009. PMID: 19414678.
Kassouf W, Agarwal PK, Grossman HB, Leibovici D, Munsell MF, Siefker-Radtke AO, Pisters LL, Swanson DA, Dinney CP, Kamat AM. Outcome of patients with bladder cancer with pN+ disease after preoperative chemotherapy and radical cystectomy. Urology 73(1):147-52, 2009. e-Pub 2009. PMID: 18848348.
Tannir NM, Thall PF, Ng CS, Wang X, Wooten L, Siefker-Radtke AO, Mathew P, Pagliaro L, Wood C, Jonasch E. A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents. J Urol 180(3):867-72; discussion 872, 2008. e-Pub 2008. PMID: 18635226.
Black PC, Brown GA, Inamoto T, Shrader M, Arora A, Siefker-Radtke AO, Adam L, Theodorescu D, Wu X, Munsell MF, Bar-Eli M, McConkey DJ, Dinney CP. Sensitivity to epidermal growth factor receptor inhibitor requires E-cadherin expression in urothelial carcinoma cells. Clin Cancer Res 14(5):1478-86, 2008. e-Pub 2008. PMID: 18316572.
Siefker-Radtke AO. Metastatic squamous cell carcinoma of the urachus: review. Clinical Advances in Hematology & Oncology 5(11):887-90, 2007. e-Pub 2007.
Kassouf W, Spiess PE, Brown GA, Munsell MF, Grossman HB, Siefker-Radtke AO, Dinney CP, Kamat AM. P0 stage at radical cystectomy for bladder cancer is associated with improved outcome independent of traditional clinical risk factors. Eur Urol 52(3):769-74, 2007. e-Pub 2007. PMID: 17434254.
Kassouf W, Spiess PE, Siefker-Radtke AO, Swanson D, Grossman HB, Kamat AM, Munsell MF, Guo CC, Czerniak BA, Dinney CP. Outcome and patterns of recurrence of nonbilharzial pure squamous cell carcinoma of the bladder: a contemporary review of The University of Texas M. D. Anderson Cancer Center experience. Cancer 110(4):764-9, 2007. e-Pub 2007. PMID: 17614317.
Kamat AM, Dinney CP, Gee JR, Grossman HB, Siefker-Radtke AO, Tamboli P, Detry MA, Robinson TL, Pisters LL. Micropapillary bladder cancer: a review of The University of Texas M. D. Anderson Cancer Center experience with 100 consecutive patients. Cancer 110(1):62-7, 2007. e-Pub 2007. PMID: 17542024.
Tannir NM, Cohen L, Wang X, Thall P, Mathew PF, Jonasch E, Siefker-Radtke AO, Pagliaro LC, Ng CS, Logothetis C. Improved tolerability and quality of life with maintained efficacy using twice-daily low-dose interferon-alpha-2b: results of a randomized phase II trial of low-dose versus intermediate-dose interferon-alpha-2b in patients with metastatic renal cell carcinoma. Cancer 107(9):2254-61, 2006. e-Pub 2006. PMID: 17029276.
Tannir N, Jonasch E, Pagliaro LC, Mathew P, Siefker-Radtke AO, Rhines L, Lin P, Tibbs R, Do KA, Lin SH, Tu SM. Pilot trial of bone-targeted therapy with zoledronate, thalidomide, and interferon-gamma for metastatic renal cell carcinoma. Cancer 107(3):497-505, 2006. e-Pub 2006. PMID: 16795067.
Kassouf W, Swanson D, Kamat AM, Leibovici D, Siefker-Radtke AO, Munsell MF, Grossman HB, Dinney CP. Partial cystectomy for muscle invasive urothelial carcinoma of the bladder: a contemporary review of the M. D. Anderson cancer center experience. J Urol 175(6):2058-62, 2006. e-Pub 2006. PMID: 16697803.
Siefker-Radtke AO, Dinney CP, Abrahams NA, Moran C, Shen Y, Pisters LL, Grossman HB, Swanson DA, Millikan RE. Evidence supporting preoperative chemotherapy for small cell carcinoma of the bladder: a retrospective review of the M. D. Anderson cancer experience. J Urol 172(2):481-4, 2004. e-Pub 2004. PMID: 15247709.
Siefker-Radtke AO, Walsh GL, Pisters LL, Shen Y, Swanson DA, Logothetis CJ, Millikan RE. Is there a role for surgery in the management of metastatic urothelial cancer? The M. D. Anderson experience. J Urol 171(1):145-8, 2004. e-Pub 2004. PMID: 14665863.
Sweeney P, Millikan R, Donat M, Wood C, Siefker Radtke AO, Pettway C, Grossman HB, Dinney C, Swanson D, Pisters L. Is there a role for post-chemotherapy retroperitoneal lymph node dissection in metastatic transitional cell carcinoma of the bladder?. J Urol 169(6):2113-7, 2003. e-Pub 2003. PMID: 12771730.
Siefker-Radtke AO, Gee J, Shen Y, Wen S, Daliani D, Millikan RE, Pisters LL. Multimodality management of urachal carcinoma: the M. D. Anderson Cancer Center experience. J Urol 169(4):1295-8, 2003. e-Pub 2003. PMID: 12629346.
Siefker-Radtke AO, Millikan RE, Tu SM, Moore DF, Smith TL, Williams D, Logothetis CJ. Phase III trial of fluorouracil, interferon alpha-2b, and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancer. J Clin Oncol 20(5):1361-7, 2002. e-Pub 2002. PMID: 11870180.
Hsi LC, Tsai AL, Kulmacz RJ, English DG, Siefker AO, Otto JC, Smith WL. Trp387 and the putative leucine zippers of PGH synthases-1 and -2. J Lipid Mediators 6(1-3):131-138, 1993. e-Pub 1993. PMID: 8357979.

Invited Articles

Siefker-Radtke AO, Curti B. Immunotherapy in Metastatic Urothelial Carcinoma: Focus on Immune Checkpoint Inhibition. Nat Rev Urol 15(2):1-14, 2018. e-Pub 2018. PMID: 29205200.
Campbell MT, Shah AY, Matin SF, Siefker-Radtke AO. Optimizing management of upper tract urothelial carcinoma. Urol Oncol 35(7):492-498, 2017. e-Pub 2017. PMID: 28579283.
Siefker-Radtke A. Urachal Adenocarcinoma: A Clinician's Guide for Treatment. Semin Oncol 39(5):619-624, 2012. e-Pub 2012. PMID: 23040259.

Manuals, Teaching Aids, Other Teaching Publications

Siefker-Radtke AO. NCCN Bladder Cancer, 2016.
Siefker-Radtke AO. NCCN Penile Cancer, 2016.
Siefker-Radtke AO, Kamat A. Bladder Cancer Practice Guidelines, 2006.
Lin EH, MD, Lozano R, RPh, DKarp D, MD. Color-Matrix Cancer Staging and Treatment Handbook, 2005.

Editorials

Andreev-Drakhlin, AY, Gao, J, Siefker-Radtke, AO. Levelling the Evidence. European urology 79(5):655-656, 2021. PMID: 32921520.
Siefker-Radtke AO. Voices: metastic urothelia carcinoma. Cancer Cell, 2021.
Andreev-Drakhlin A, Gao J, Siefker-Radtke AO. Levelling the Evidence: A Comparison of Neoadjuvant and Adjuvant Treatment for Upper Tract Urothelial Carcinoma. European Urology, 2020.
Shah AY, Gao J, Siefker-Radtke AO. Five new therapies or just one new treatment? A critical look at immune checkpoint inhibition in urothelial cancer. Immunotherapy 9(10):781-784, 2017. PMID: 28877627.
Siefker-Radtke AO, Campbell MT. Now is the time for perioperative chemotherapy in upper tract urothelial cancer. J Clin Oncol 35(8):816-817, 2017. PMID: 28165904.
Siefker-Radtke A. Editorial Comment. J Urol 195(6):1696, 2016. PMID: 26970453.
Siefker-Radtke AO, Gao J. Towards effective adjuvant treatment for urothelial cancer. Lancet Oncol 16(1):9-10, 2015. PMID: 25498220.
Siefker-Radtke A. Dose-dense makes sense: Emerging concepts in urothelial cancer. Genitourinary Cancers Symposium Daily News(1):18, 2011.
Logothetis CJ, Siefker-Radtke A. Re: Final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium. Eur Urol 57(4):728-9, 2010.
Siefker-Radtke AO. Surgical consolidation of initially unresectable urothelial carcinoma: an incremental opportunity to cure. Expert Rev Anticancer Ther 9(12):1701-3, 2009. PMID: 19954279.

Abstracts

Siefker-Radtke AO, Powels T, Moreno V, . Erdafitinib (ERDA) vs ERDA plus cetrelimab (ERDA+CET) for patients (pts) with metastatic urothelial carcinoma (mUC) and fibroblast growth factor receptor alterations (FGFRa): Final results from the phase 2 norse study. 2023 ASCO Annual Meeting, 2023. e-Pub 2023.
Shah A, Campbell M, Tidwell R, Siefker-Radtke A, GoswamiS, Alhalabi O, Adriazola A, Shaw L, Ye Y, Chen J, Yan X, Wang L, Gao J. A phase II trial evaluating combination pemetrexed and avelumab in patients with MTAP-deficient advanced urothelial cancer. 2022 ASCO Annual Meeting, 2022. e-Pub 2022.
Gupta S, Bellmunt J, Plimack E, Sonpavde G, Grivas P, Apolo A, Pal S, Siefker-Radtke A, Flaig T, Galsky M, Rosenberg J. Defining “platinum-ineligible” patients with metastatic urothelial cancer (mUC). 2022 ASCO Annual Meeting, 2022. e-Pub 2022.
Alhalabi O, Siefker-Radtke AO. Factors associated with improved outcomes in surgically respectable small cell urothelial cancer (SCUC). 2022 GU ASCO Annual Meeting, 2022. e-Pub 2022.
Loriot Y, Siefker-Radtke A, et al. First-line pembrolizumab (pembro) with or without lenvatinib (lenva) in patients with advanced urothelial carcinoma (LEAP-011): A phase 3, randomized, double-blind study. 2022 ASCO Genitourinary Cancers Symposium, 2022. e-Pub 2022.
McGregor B, Xie W, Bilen M, Campbell M, Mortazavi A, HuangJ, Sunkara R, Ravi P, Shah A, Baca S, Sonpavde G, Bellmunt J, Siefker-Radtke A, Signoretti S, Van Allen E, Beltran H, McKay R, Choueiri T. Initial results of a phase II study of nivolumab(N) and ipilimumab(I) in genitourinary malignancies with neuroendocrine differentiation. 2022 ASCO Genitourinary Cancers Symposium, 2022. e-Pub 2022.
Grivas P, Siefker-Radtke A. PIVOT IO 009: A phase 3, randomized study of neoadjuvant and adjuvant nivolumab (NIVO) plus bempegaldesleukin (BEMPEG; NKTR-214) versus NIVO alone versus standard of care (SOC) in patients (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin (cis)-ineligible. 2022 ASCO Genitourinary Cancers Symposium, 2022. e-Pub 2022.
Feils A, Erbe A, Birstler J, Kim K, Hoch U, Currie S, Nguyen T, Yu D, Siefker-Radtke A, Tannir N, Hellmann M, Tolaney S, Diab A, Sondel P. 59 Associations between KIR/KIR-ligand genotypes and clinical outcome for patients with advanced solid tumors receiving BEMPEG plus nivolumab combination therapy in the PIVOT-02 trial. Journal for ImmunoTherapy of Cancer 2021, 2021. e-Pub 2021.
Hensley PJ, Bree KK, Campbell MT, Alhalabi O, Kokorovic A, Miest T, Nogueras-Gonzalez GM, Gao J, Siefker-Radtke AO, Guo CC, Naval N, Dinney CP, Kamat AM. Progression of Disease after Bacillus Calmette-Guérin Therapy: Refining Patient Selection for Neoadjuvant Chemotherapy before Radical Cystectomy. AUA 2021 Annual Meeting / The Journal of Urology, 2021. e-Pub 2021.
Wilson N, Alhalabi O, Hasanov, Xiao L, Papadopoulos J, Campbell M, Shah A, Gao J, Corn P, Aparicio A, Wang J, Czerniak B, Guo C, Logothetis C, Li J, Choi S, Tang C, Tannir N, Siefker-Radtke A. 241 Immune checkpoint blockade (ICB) in brain metastases (BM) from advanced small cell urothelial cancer (aSCUC). Journal for ImmunoTherapy of Cancer 2021, 2021. e-Pub 2021.
Hensley P, Bree K, Campbell M, Alhalabi O, Kokorovic A, Miest T, Gonzalez G, Gao J, Siefker-Radtke A, Guo C, Naval N, Grossman HB, Dinney C, Karnat A. PD51-06 PROGRESSION AFTER BCG THERAPY: REFINING PATIENT SELECTION FOR NEOADJUVANT CHEMOTHERAPY BEFORE RADICAL CYSTECTOMY. The Journal of Urology, 2021. e-Pub 2021.
Powles T, Chistyakov V, Beliakouski V, Semenov A, Everaert E, Baranau Y, Moreno V, Perez Valderrama B, Vano Y, Del Conte G, Loriot Y, Kang T, Tammaro M, O'Hagan A, Hosseini M, Triantos S, Chhabra H, Santiago-Walker A, Siefker-Radtke A. LBA27 - Erdafitinib (ERDA) or ERDA plus cetrelimab (CET) for patients with metastatic or locally advanced urothelial carcinoma (mUC) and Fibroblast Growth Factor Receptor alterations (FGFRa): First phase (Ph) II results from the NORSE study. ESMO Congress 2021, 2021. e-Pub 2021.
Siefker-Radtke A, Hoch U, Loriot Y, Balar A, Bilen M, Tannir N, Cho D, Choudhury A, Chien D, Yu D, Currie S, Novotny J, Santiago L, Tagliaferri M, Zalevsky J, Huddart R. 83P - Evaluation of concordance between PD-L1 immunohistochemistry 28-8 and 22C3 pharmDx assays in metastatic urothelial carcinoma (mUC) in PIVOT-10. ESMO Congress 2021, 2021. e-Pub 2021.
Msaouel P, Gao J, Yuan, Y Siefker-Radtke A, Jonasch E, Goswami S, Zurita A, Campbell M, Shah A, Corn P, Ramos C, Yan X, Chin C, Der-Torossian H, Tannir N. Phase I/IB trial of sitravatinib (Sitra) + nivolumab (Nivo) + ipilimumab (Ipi) in patients (pts) with advanced clear cell renal cell carcinoma (accRCC) or other solid malignancies. 2021 Genitourinary Cancers Symposium, 2021. e-Pub 2021.
Alhalabi O, Siefker-Radtke A. Survival outcomes in patients receiving immune checkpoint inhibitor (ICI) for metastatic small cell urothelial cancer (SCUC). 2021 ASCO Annual Meeting, 2021. e-Pub 2021.
Siefker-Radtke AO. Management of fibroblast growth factor receptor inhibitor (FGFRi) treatment-emergent adverse events (TEAEs) of interest in patients (Pts) with locally advanced or metastatic urothelial carcinoma (mUC). 2021 GU ASCO, 2021. e-Pub 2021.
Siefker-Ratke A. Enfortuamab Vedotin in Previously Treated Urothelial Cancer. 2021 GU ASCO Annual Meeting, 2021. e-Pub 2021.
Fleming S, Gifkins D, Shalaby W, Gao J, Rosenberg P, Gaj C, Crawford A, Lu-Yao G, Maio V, Siefker-Radtke A. Fibroblast growth factor receptor alteration (FGFRa) status and progression outcomes of patients with advanced or metastatic urothelial cancer (mUC). 2021 ASCO Annual Meeting, 2021. e-Pub 2021.
Andreev-Drakhlin A, Shah A, Adrizola A, Shaw L, Lopez L, James M, Matin S, Alhalabi O, Gao J, Siefker-Radtke A, Goswami S, Xiao L, Venkatesan A, Campbell M. Efficacy of immune checkpoint blockade in patients with advanced upper tract urothelial cancer and mismatch repair deficiency or microsatellite instability (MSI). 2021 Genitourinary Cancers Symposium, 2021. e-Pub 2021.
Rezazadeh A, Loriot Y, Papantoniou D, Siefker-Radtke A, Necchi A, Naini V, Santiago-Walker A, Galluzzi A, Monga M, Burgess E. An observational study of outcomes of patients (pts) with advanced urothelial carcinoma (UC) after anti-programmed death-(Ligand) 1 (PD-[L]1) therapy by fibroblast growth factor receptor gene alteration (FGFRa) status. 2020 ESMO Congress, 2020. e-Pub 2020.
Siefker-Radtke, et al. Analysis of circulating tumor DNA (ctDNA) from the phase II BLC2001 trial of erdafitinib in locally advanced or metastatic urothelial carcinoma (mUC) to identify markers of intrinsic resistance to fibroblast growth factor receptor (FGFR)-targeted therapy. 2020 ESMO Congress, 2020. e-Pub 2020.
Siddiqui B, Gheeya J, Goswamy R, Subudhi S, Gao J, Campbell M, Shah A, Msaouel P, Zurita-Saavedra A, Goswami S, Wang J, Jonasch E, Siefker-Radtke A, Sharma P, Tannir N. Immune checkpoint therapy (ICT) re-challenge after immune-related adverse events (irAEs) in genitourinary cancers (GUC). 2020 ESMO Congress, 2020. e-Pub 2020.
Necchi A, Siefker-Radtke A, et al. Erdafitinib (ERDA) in patients (pts) with locally advanced or metastatic urothelial carcinoma (mUC): Subgroup analyses of long-term efficacy outcomes of a pivotal phase II trial (BLC2001). 2020 ESMO Congress, 2020. e-Pub 2020.
Msaouel P, Siefker-Radtke A, Sweis R, Mao S, Rosenberg J, Vaishampayan U, Rezazadeh Kalebasty A, Pili R, Bupathi M, Nordquist L, Shaffer D, Davis N, Zhang T, Gandhi S, Christensen J, Shazer R, Yan X, Winter M, Der-Torossian H, Vasudeva Iyer G. 705MO - Sitravatinib (sitra) in combination with nivolumab (nivo) demonstrates clinical activity in checkpoint inhibitor (CPI) naïve, platinum-experienced patients (pts) with advanced or metastatic urothelial carcinoma (UC). ESMO Congress 2020, 2020. e-Pub 2020.
Alhalabi O, Hahn A, Msaouel P, Meric-Bernstam F, Naing A, Piha-Paul S, Janku F, Pant S, Yap T, Hong D, Fu S, Karp D, Campbell E, Campbell M, Shah A, Tannir N, Siefker-Radtke A, Gao J, J Roszik J, Subbiah V. Validation of prognostic scores in patients with metastatic bladder carcinoma (mBC) enrolled in early phase clinical trials. ESMO Congress 2020, 2020. e-Pub 2020.
Siefker-Radtke A, et al. Updated data from the NORSE trial of erdafitinib (ERDA) plus cetrelimab (CET) in patients (pts) with metastatic or locally advanced urothelial carcinoma (mUC) and specific fibroblast growth factor receptor (FGFR) alterations. 2020 ESMO Congress, 2020. e-Pub 2020.
Sharma P, Siefker-Radtke A, et al. Nivolumab (N) alone or in combination with ipilimumab (I) in patients (pts) with platinum-pretreated metastatic urothelial carcinoma (mUC): Extended follow-up from CheckMate 032. 2020 ESMO Congress, 2020. e-Pub 2020.
Siefker-Radtke AO. Clinical outcomes and economic burden for bladder cancer patients: An analysis from a Swedish cancer registry. 2020 ASCO Annual Meeting, 2020. e-Pub 2020.
Siefker-Radtke AO, Necchi A, Park SH, García-Donas J, Huddart RA, Burgess EF, Fleming MT, Rezazadeh A, Mellado B, Varlamov S, Joshi M, Duran I, Tagawa ST, Zakharia Y, Qi K, Monga M, Sondhi M, Ohagan A, Loriot Y. Outcomes and the impact of genomic characteristics on patients with metastatic urothelial carcinoma enrolled in early phase trials. 2020 ASCO Annual Meeting, 2020. e-Pub 2020.
Huddart R, Siefker-Radtke AO, Balar A, Bilen M, Powles T, Bamias A, Castellano D, Khalil M, Van Der Heijden M, Koshkin V, Pook D, Ozguroglu M, Santiago L, Saab R, Li P, Tagliaferri MC, Lin W, Tagliaferri M, Loriot Y. PIVOT-10: A phase II study of bempegaldesleukin (NKTR-214) in combination with nivolumab (NIVO) in cisplatin (cis) ineligible patients with previously untreated locally advanced or metastatic urothelial cancer (mUC). J Clin Oncol, 2020. e-Pub 2020.
Moreno V, Loriot Y, Valderrama B, Beato C, Vano Y, Fleming M, Duran I, Siena S, Tolbert J, OHagan A, Akapame S, Lau Y, Geoffrois L, Tagawa S, Mellado B, Siefker-Radtke AO. Does escalation results from phase Ib/II Norse study of erdafitinib (ERDA) + PD-1 inhibitor JNJ-63723283 (Cetrelimab [CET]) in patients (pts) with metastatic or locally advanced urothelial carcinoma (mUC) and selected fibroblast growth factor receptor (FGFR) gene alterations. J Clin Oncol, 2020. e-Pub 2020.
Loriot Y, Balar A, De Wit R, Garcia J, Grivas P, Matsubara N, Moreno B, Sbar E, Jia X, Dutcus C, Siefker-Radtke AO, Roussy G. Phase III study of first-line pembrolizumab (pembro) plus lenvatinib (len) in patients (pts) with advanced urothelial carcinoma (UC) ineligible for platinum-based chemotherapy: LEAP-011. J Clin Oncol, 2020. e-Pub 2020.
Siefker-Radtke AO, Steinberg G, Bedke J, Nishiyama H, Fang X, Kataria R, Moreno B, Hoimes C. Phase III study of perioperative pembrolizumab (pembro) plus neoadjuvant chemotherapy (chemo) versus placebo plus neoadjuvant chemo in cisplatin-eligible patients (pts) with muscle-invasive bladder cancer (MIBC): KEYNOTE-866. 2020 Genitourinary Cancers Symposium, 2020. e-Pub 2020.
Chaudhry A, Sternberg C, De Santis M, Bellmunt J, Necchi A, Powles T, Cantero F, Marszewska M, Grzyb M, McSheehy P, Braun S, Siefker-Radtke AO. FIDES-02, a phase Ib/II study of derazantinib (DZB) as monotherapy and combination therapy with atezolizumab (A) in patients with surgically unresectable or metastaticurothelial cancer (UC) and FGFR genetic aberrations. J Clin Oncol, 2020. e-Pub 2020.
Siefker-Radtke A. Precision Therapy in Urothelial Cancer: New Molecular Enrichment Approaches. 2020 ASCO Virtual Education Program, 2020. e-Pub 2020.
Siefker_Radtke A. ERDAFITINIB in locally advanced or metastatic urothelial carcinoma (mUC): Long-term outcomes in BLC2001. 2020 ASCO Virtual Scientific Program, 2020. e-Pub 2020.
Tagawa S, Siefker-Radtke A, Dosne A, Zhong B, Qi K, Shalaby W, O’Hagan A, Porre P, Mahadevia P, Loriot Y. Hyperphosphatemia due to erdafitinib (a pan-FGFR Inhibitor) and anti-tumour activity among patients (Pts) with advanced urothelial carcinoma (UC). 2019 ESMO Congress, 2019. e-Pub 2019.
Loriot Y, Balar A, de Wit R, Garcia JA, Grivas P, Matsubara N, Frenkl TL, Sbar E, Jia XC, Fouad T, Siefker-Radtke AO. Phase III LEAP-011 trial: First-line pembrolizumab with lenvatinib in patients with advanced urothelial carcinoma ineligible to receive platinum-based chemotherapy. 2019 ESMO Congress, 2019. e-Pub 2019.
Siefker-Radtke AO, Steinberg G, Bedke J, Nishiyama H, Martin J, Kataria R, Frenkl TL, Hoimes CJ. Phase III study of perioperative pembrolizumab (pembro) or placebo (pbo) in combination with neoadjuvant chemotherapy in cisplatin (cis)-eligible patients (pts) with muscle-invasive bladder cancer. 2019 ESMO Congress, 2019. e-Pub 2019.
Siefker-Radtke AO, Zhong B, Qi K, Shalaby W, De Porre P, O’Hagan A, Mahadevia P, Loriot Y. Analysis of response to prior therapies and therapies after treatment with erdafitinib in fibroblast growth factor receptor (FGFR)-positive patients (pts) with metastatic urothelial carcinoma (mUC). 2019 ESMO Congress, 2019. e-Pub 2019.
Matulay JT, Campbell MT, Narayan VM, Seif MA, Lim AH, Shah AY, Msaouel P, Gao J, Siefker-Radtke AO, Dinney CPN, Kamat AM, Navai N. Pathologic outcomes after neoadjuvant chemotherapy for high-risk muscle invasive bladder cancer. 2019 ESMO Congress, 2019. e-Pub 2019.
Siefker-Radtke AO, Lugowska I, Tupikowski K, Andric ZG, Rezazadeh Kalebasty A, Curigliano G, Vaena D, Vogl FD, Currie G, Abella S, Kelly W. Clinical activity of vofatamab (V), an FGFR3 selective antibody in combination with pembrolizumab (P) in metastatic urothelial carcinoma (mUC), updated interim analysis of FIERCE-22. 2019 ESMO Congress, 2019. e-Pub 2019.
Loriot Y, Van Sanden S, Diels J, Rahhali N, Seshagiri D, Kowalski B, Fleming S, De Porre P, Siefker-Radtke AO. Erdafitinib (erda) versus available therapies in advanced urothelial cancer: A matching adjusted indirect comparison. 2019 ESMO Congress. e-Pub 2019.
Siddiqui B, Durand J, Gao J, Wang J, Aparicio A, Campbell M, Siefker-Radtke AO, Tannir N, Corn P, Msaouel P, Shah A, Zurita A, Tu SM, Suarez-Almazor M, Sudhakar T, Logothetis C, Sharma P, Subudhi SK. Clinical and immunological analyses of immune checkpoint inhibitor-associated neuromuscular (NM) toxicities. J Clin Oncol, 2019. e-Pub 2019.
Choi W, McConkey D, Lee ID, Currie G, Abella E, Kelly W, Siefker-Radtke AO. Gene Expression Profiling in Wildtype and Mutant FGFR3 Metastatic Urothelial Cancer Treated With Combination Therapy With Vofatamab and Pembrolizumab. 2019 Bladder AACR, 2019. e-Pub 2019.
Choi S, Campbell M, Shah A, Navai N, Kamat A, Dinney C, Nguyen Q, Siefker-Radtke AO. Prophylactic cranial irradiation (PCI) significantly decreases risk of brain metastases in patients with bulky, higher stage small-cell urothelial cancer. 2019 Genitourinary Cancers Symposium, 2019. e-Pub 2019.
Siefker-Radtke AO, Loriot Y, Moy C, Cherkas Y, Motley C, Avadhani A, O'Hagan A, De Porre P, Lorenzi M, Mccaffery I. Erda ctDNA. 2019 GU ASCO, 2019. e-Pub 2019.
Santiago-Walker A, Moy C, Cherkas Y, Loriot Y, Siefker-Radtke AO, Motley C, Avadhani A, OHagan A, De Porre P, Lorenzi M, McCaffery I. Analysis of FGFR alterations from circulating tumor DNA (ctDNA) and Tissue in a phase II trial of erdafitinib in urothelial carcinoma (UC). J Clin Oncol, 2019. e-Pub 2019.
Santiago-Walker A, Chen F, Loriot Y, Siefker-Radtke AO, Sun L, Sundaram R, De Porre P, Patel K, Wan Y. Predictive value of fibroblast growth factor receptor (FGFR) mutations and gene fusions on anti-PD-(L)1 treatment outcomes in patients (pts) with advanced urothelial cancer (UC). J Clin Oncol, 2019. e-Pub 2019.
Siefker-Radtke AO, Balar A, Fishman MN, Giovanni G, Gao J, Diab A, Bilen MA. NKTR-214 + nivolumab in first-line advanced/metastatic urothelial carcinoma (mUC): Updated results from PIVOT-02. 2019 GU ASCO, 2019. e-Pub 2019.
Alhalabi O, Campbell M, Slack-Tidwell R, Siefker-Radtke AO, Shah A, Efstathiou E, Wang W, Titus M, Czerniak B, Zhang M, Guo C, Logothetis C, Gao J. A phase II trial to evaluate pemetrexed clinical responses in relation to tumor methylthioadenosine phosphorylase (MTAP) gene status in patients with previously treated metastatic urothelial carcinoma. J Clin Oncol, 2019. e-Pub 2019.
Msaouel P, Slack-Tidwell R, Genovese G, Daw N, Siefker-Radtke AO, Tannir N. Phase II trial of ixazomib combined with gemcitabine and doxorubicin in patients with SMARCB1-deficient kidney malignancies. J Clin Oncol, 2019. e-Pub 2019.
Siefker-Ratke A. FIERCE-22: Clinical activity of vofatamab (V) a FGFR3 selective inhibitor in combination with pembrolizumab (P) in WT metastatic urothelial carcinoma, preliminary analysis. 2019 ASCO Annual Meeting, 2019. e-Pub 2019.
Rosenberg JE, Sharma P, de Braud FGM, Basso U, Calvo E, Bono P, Morse M, Ascierto PA, Lopez-Martin JA, Brossart P, Rohrberg KS, Reguart N, Lin WH, Meadows-Shropshire S, Saci A, Callahan M, Siefker-Radtke AO. Nivolumab (N) Alone or in Combination With Ipilimumab (I) in Patients (pts) With Platinum Pretreated Metastatic Urothelial Carcinoma (mUC). ESMO 2018 Congress, 2018. e-Pub 2018.
Sharma P, Baron A, Necchi A, Plimack ER, Pal SK, Bedke J, Arranz JA, Vaena D, Grimm M, Bracarda S, Retz M, Siefker-Radtke AO, Ohyama C, Grossfeld G, Lu H, Saci A, Tang H, Galsky MD. Abstract CT178: Nivolumab monotherapy in patients with advanced platinum-resistant urothelial carcinoma: Efficacy and safety update and association between biomarkers and overall survival in CheckMate 275. AACR Annual Meeting 78(13), 2018. e-Pub 2018.
Diab A, Hurwitz ME, Cho DC, Papadimitrakopoulou V, Curti BD, Tykodi SS, Puzanov I, Ibrahim NK, Tolaney SM, Tripathy D, Gao J, Siefker-Radtke AO, Clemens W, Tagliaferri MA, Gettinger SN, Kluger HM, Larkin JMG, Grignani G, Sznol M, Tannir NM. NKTR-214 (CD122-biased agonist) plus nivolumab in patients with advanced solid tumors: Preliminary phase 1/2 results of PIVOT. ASCO 2018 Annual Meeting, 2018. e-Pub 2018.
Gao J, Siefker-Radtke AO, Navai N, Campbell MT, Slack R, Guo C, Kamat AM, Matin SF, Papadopoulos JN, Araujo JC, Shah AY, Blando JM, Vence LM, Duan F, Basu S, Singh S, Zhao H, Dinney C, Sharma P. A pilot pre-surgical study evaluating anti-PD-L1 durvalumab (durva) plus anti-CTLA-4 tremelimumab (treme) in patients with muscle-Invasive, high-risk urothelial bladder carcinoma who are ineligible for cisplatin-based neoadjuvant chemotherapy. J Clin Oncol, 2018. e-Pub 2018.
Siefker-Radtke AO, Necchi A, Rosenbaum E, Culine S, Burgess EF, O'Donnell PH, Tagawa ST, Zakharia Y, Loriot Y. Efficacy of programmed death 1 (PD-1) and programmed death 1 ligand (PD-L1) inhibitors in patients with FGFR alterations: results from a data analysis of an ongoing Phase 2 study of erdafitinib (JNJ-42756493) in patients (pts) with advanced urothelial cancer (UC). 2018 Genitourinary Cancers Symposium, 2018. e-Pub 2018.
Galsky MD, Saci A, Szabo PM, Wang L, Zhu J, Azrilevich A, Fischer BS, Necchi A, Siefker-Radtke AO, Sharma P. Fibroblast growth factor receptor 3 (FGFR3), peroxisome proliferator-activated receptor gamma (PPARg), and outcomes with nivolumab (nivo) in metastatic urothelial cancer (UC). 2018 Genitourinary Cancers Symposium, 2018. e-Pub 2018.
Loriot Y, Necchi A, Park SH, Garcia-Donas, Huddart R, Burgess E, Fleming M, Rezazadeh A, Mellado B, Varlamov S, Joshi M, Duran I, O'Hagan A, Avadhani A, Zhong B, Stuyckens K, Dosne AG, Siefker-Radtke AO. Erdafitinib (ERDA; JNJ-42756493), a pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR2 and FGFR3 alterations (FGFR+): phase 2 continuous (cont) vs intermittent (int) dosing. 2018 Genitourinary Cancers Symposium, 2018. e-Pub 2018.
Santiago-Walker A, Chen F, Loriot Y, Siefker-Radtke AO, Sun L, Sundaram R, De Porre P, Patel K, Wan Y. Predictive value of fibroblast growth factor receptor (FGFR) mutations and gene fusions on anti-PD-(L)1 treatment outcomes in patients (pts) with advanced urothelial cancer (UC). 2018 GU ASCO, 2018. e-Pub 2018.
Santiago-Walker A, Moy C, Cherkas Y, Loriot Y, Siefker-Radtke AO, Motley C, Avadhani A, O'Hagan A, De Porre P, Lorenzi MV, McCaffery I. Analysis of FGFR alterations from circulating tumor DNA (ctDNA) and Tissue in a phase II trial of erdafitinib in urothelial carcinoma (UC). 2018 GU ASCO, 2018. e-Pub 2018.
Bedke J, Sharma P, Retz M, Siefker-Radtke AO, Necchi A, Plimack ER, Vaena D, Grimm MO, Bracarda S, Arranz JA, Pal S, Ohyama C, Gruellich C, Von Amsverg G, Steiner T, Saci A, Lambert A, Azrilevich A, Galsky MD. Efficacy Update of Nivolumab Monotherapy in Patients With Metastatic or Surgically Unresectable Locally Advanced Urothelial Carcinoma Who Have Received Prior Treatment: Phase II Checkmate 275 Study. Annual Meeting of Germans, Austrian and Swiss companies for Hematology and Medical Oncology, German Society of Hematology and Oncology (DGHO), 2017. e-Pub 2017.
Galsky MD, Saci A, Szabo PM, Azrilevich A, Horak C, Lambert A, Siefker-Radtke AO, Necchi A, Sharma P. Impact of tumor mutation burden on nivolumab efficacy in second-line urothelial carcinoma patients: exploratory analysis of the phase II checkmate. ESMO 2017 Congress, An Oncol 28(5), 2017. e-Pub 2017.
Choi W, Sundi D, Metcalfe M, Lee I, Pretzsch S, Bondaruk J, Plimack E, Siefker-Radtke AO, Czerniak B, Dinney C, McConkey. Impact of molecular subtypes on predicting chemotherapy response and survival in muscle invasive bladder cancer. 2017 American Association for Cancer Research Meeting 77(13), 2017. e-Pub 2017.
Siefker-Radtke AO, Mellado B, Decaestecker K, Burke JM, O'Hagan A, Avadhani A, Zhong B, Santiago-Walker A, Brookman-May S, De Porre P, Garcia-Donas J. Ongoing phase 2 study of erdafitinib (JNJ-42756493), a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients (pts) with metastatic or unresectable urothelial carcinoma (M/UR UC) and FGFR gene alterations. 2016 ESMO Congress, 2016. e-Pub 2016.
Siefker-Radtke AO, Mellado B, Decaesteck K, Burke JM, O'Hagan A, Avadhani AN, Zhong B, Santiago-Walker AE, De Porre P, Brookman-May S, Garcia-Donas J. A phase 2 study of JNJ-42756493, a pan-FGFR tyrosine kinase inhibitor, in patients (pts) with metastatic or unresectable urothelial cancer (UC) harboring FGFR gene alterations. 2016 ASCO Annual Meeting, 2016. e-Pub 2016.
Kamat AM, Bellmunt J, Choueiri TK, Nam K, DeSantis M, Dreicer R, Hahn NM, Perini RF, Siefker-Radtke AO, Sonpavde G, DeWit R, Witjes A, Keefe SM, Bajorin DF. KEYNOTE-057: Phase 2 study of pembrolizumab for patients (pts) with Bacillus Calmette Guerin (BCG)-unresponsive, high-risk non-muscle-invasive bladder cancer (NMIBC). 2016 ASCO Annual Meeting, 2016. e-Pub 2016.
Benson C, Navai N, Gao J, Siefker-Radtke AO, Nogueras Gonzalez G, Golla V, Alliston J, Kamat A, Dinney C, Shah J. MP49-12 Neoadjuvant chemotherapy for invasive bladder cancer: Is it right for everyone?. 2016 American Urological Association Meeting, 2016. e-Pub 2016.
Siefker-Radtke AO, Zhang X, Guo CC, Pirollo KF, Chang EH, Millikan RE, Benedict W. Systemic administration using targeted gene delivery with SGT-RB94 shows evidence of tumor targeting and anticancer activity: a phase I first-in-man trial. 2016 American Association for Cancer Research Meeting, 2016. e-Pub 2016.
Campbell MT, McConkey D, Matin SF, Kamat AM, Dinney C, Wang J, Gao J, Siefker-Radtke AO. The hotspot mutational landscape of upper tract and bladder urothelial cancers and correlation to survival. 2016 GU ASCO Meeting, 2016. e-Pub 2016.
Mmeje CQ, Slade A, Slack R, Navai N, Gao J, Siefker-Radtke AO, Kamat AM, Dinney C, Shah J. The utility of neutrophil-to-lymphocyte ratio in determining survival outcomes in patients treated with neoadjuvant chemotherapy and radical cystectomy for high-risk bladder cancer. 2016 GU ASCO Meeting, 2016. e-Pub 2016.
Siefker-Radtke AO. Current Challenges in Managing Bladder Cancer. 2015 Society of Urologic Oncology Meeting, 2015. e-Pub 2015.
Mmeje, CH, Benson, C, Nogueras-Gonzalez GM, Jayaratna IS, Navai N, Gao J, Siefker-Radtke AO, Kamat AM, Dinney CP, Shah JB. Determining the optimal timing for radical cystectomy after neoadjuvant chemotherapy. American Urological 2015 Annual Meeting, 2015. e-Pub 2015.
Fernandez M, Williams SB, Willis D, Slack R, Dickstein R, Parikh S, Siefker-Radtlke AO, Guo CC, Czernial BA, Shah JB, Pisters LL, Grossman HB, Dinney CP, Kamat AM. Outcome of Patients with Micropapillary Bladder Cancer treated with Radical Cystectomy with/without Neoadjuvant Chemotherapy. American Urological Association 2015 Meeting, 2015. e-Pub 2015.
Ho PL, Willis DL, Patil J, Tart K, Parikh S, Shah JB, Delacroix SE, Siefker-Radtke AO, Dinney CP, Pisters LL, Kamat AM. Outcome of patients with clinically node-positive bladder cancer who undergo consolidative surgery after preoperative chemotherapy: MD Anderson Cancer Center experience. 2014 Genitourinary Cancers Symposium, 2014. e-Pub 2014.
Siefker-Radtke AO, Choi W, Melquist J, Shen Y, Kamat A, Matin S, Millikan R, Dinney CP, Czerniak BA, McConkey DJ. Gene expression profiling in the context of neoadjuvant chemotherapy with DDMVAC+B (dose dense methotrexate, vinblastine, doxorubicin, cisplatin, and bevacizumab) can predict clinical outcomes and tumor biology. AACR 2014 Meeting, 2014. e-Pub 2014.
Porten SP, Siefker-Radtke AO, Kamat AM, Dinney CPN, Matin SF. Survival outcomes in patients undergoing neoadjuvant chemotherapy for upper tract urothelial cell carcinoma. 2013 ASCO GU Symposium, 2013. e-Pub 2013.
Willis DL, Fernandez M, Dickstein RJ, Parikh S, Siefker-Radtke AO, Guo C, Czerniak B, Shah JB, Pisters LL, Grossman HB, Dinney CPN, Kamat AM. Outcome of patients with micropapillary bladder cancer treated with neoadjuvant therapy and radical cystectomy. 2013 ASCO GU Symposium, 2013. e-Pub 2013.
Dinney CPN, Choi W, Porten SP, Roth B, Cheng T, Willis DL, Tran MN, Lee IC, Bondaruk JE, Majewski T, Zhang S, Pretzsch SM, Baggerly KA, Siefker-Radtke AO, Czerniak B, McConkey DJ. A STAT3- and p63-dependent transcriptional network to define a lethal basal subset of human bladder cancers. 2013 ASCO Annual Meeting, 2013. e-Pub 2013.
Porten SP, Gopalakrishnan V, Nogueras-Gonzalez GM, Kamat AM, Siefker-Radtke AO, Dinney CPN, Matin SF. Survival of upper tract urothelial carcinoma: A population-based analysis. 2013 Genitourinary Cancers Symposium, 2013. e-Pub 2013.
Siefker-Radtke AO, Wen S, Shen Y, Stigall K, McConkey DJ, Millikan RE. A novel phase I trial design featuring a two-dimensional dose-finding algorithm optimizing the dose of gemcitabine and doxorubicin with bortezomib in metastatic urothelial carcinoma (UC). 2013 ASCO Annual Meeting, 2013. e-Pub 2013.
PortenS, Siefker-Radtke AO, Kamat A, Dinney C, Matin S. Survival outcomes in patients undergoing neoadjuvant chemotherapy for upper tract urothelial cell carcinoma. American Urological Association 2013 Meeting, 2013. e-Pub 2013.
Pagliaro LC, Munsell MF, Harris D, Carolla RL, Siefker-Radtke AO. Gemcitabine, paclitaxel, and doxorubicin as first-line therapy for patients with advanced urothelial carcinoma and renal insufficiency: A phase II study. 2013 ASCO Annual Meeting, 2013. e-Pub 2013.
Grivas P, Agarwal N, Siefker-Radtke, AO, Daignault S, Puzanov I, MacVicar GR, Levine EG, Srinivas S, Twardowski P, Eisenberger MA, Quinn DI, Vaishampayan UN, Yu EY, Dawsey S, Day KC, Day ML, Smith DC, Hussain M. Randomized phase II trial of gemcitabine/cisplatin (GC) with or without cetuximab (CET) in patients (pts) with advanced urothelial carcinoma (UC). 2012 ASCO Annual Meeting, 2012. e-Pub 2012.
Siefker-Radtke AO, Kamat AM, Corn PG, Matin SF, Grossman HB, Millikan RE, Dinney CPN. Neoadjuvant chemotherapy with DD-MVAC and bevacizumab in high-risk urothelial cancer: Results from a phase II trial at the University of Texas M. D. Anderson Cancer Center. 2012 ASCO Annual Meeting, 2012. e-Pub 2012.
Dayyani F, Munsell MF, Siefker-Radtke AO. Incidence of peritoneal carcinomatosis in recurrent plasmacytoid urothelial carcinomas (PUC) of the bladder: A retrospective analysis of patient outcomes at M. D. Anderson Cancer Center (MDACC). 2012 ASCO Annual Meeting, 2012. e-Pub 2012.
Siefker-Radtke AO, Kamat AM, Corn PG, Matin SF, Grossman HB, Millikan RE, Dinney CPN. Neoadjuvant chemotherapy with DD-MVAC and bevacizumab in high-risk urothelial cancer: Results from a phase II trial at the M. D. Anderson Cancer Center. 2012 ASCO GU Symposium, 2012. e-Pub 2012.
Navai N, Williams MB, Wen S, Siefker-Radtke AO, McConkeyDJ, Dinney CPN, Adam L. Relationship between high microRNA-200C expression and the risk of death from disease in muscle-invasive urothelial carcinoma of the bladder. 2012 Genitourinary Cancers Symposium, 2012. e-Pub 2012.
Aparicio A, Sun J, Tang DN, Arap W, Araujo J, Corn P, Tannir N, Wang X, Siefker-Radtke AO, Sharma P. A phase II study of ipilumimab plus androgen deprivation therapy in castraton-sensitive prostate carcinoma. AACR 2012 meeting, 2012. e-Pub 2012.
Pagliaro LC, Munsell M, Harris D, Carolla RL, Siefker-Radtke AO. Gemcitabine, paclitaxel and doxorubicin for patients (pts) with urothelial carcinoma (UC) and renal insufficiency: Preliminary results of a multicenter phase II study. 2011 ASCO GU Symposium, 2011. e-Pub 2011.
Choi W, Shah JB, Tran M, Svatek RS, Marquis L, Lee IC, Yu D, Adam L, Bondaruk JE, Wen S, Shen Y, Dinney CPN, Czerniak B, McConkey DJ, Siefker-Radtke AO. Use of P63 expression to define a lethal subset of muscle-invasive bladder cancers. 2011 ASCO Annual Meeting, 2011. e-Pub 2011.
Lynch SP, Vu TT, Kamat, AM, Grossman HB, Millikan RE, Dinney CP, Siefker-Radtke AO. The Impact of neoadjuvant chemotherapy in small cell carcinoma of the bladder: The MD Anderson Cancer Center experience. 2010 ASCO Annual Meeting, 2010. e-Pub 2010.
Siefker-Radtke AO, Margulis V, Kamat A, Grossman B, Wood C, Millikan R, Dinney C, Matin S. Evidence for neoadjuvant chemotherapy for high-grade upper-tract urothelial cancer: a retrospective review from the M. D. Anderson Cancer Center. 2010 ASCO GU Symposium(282), 2010. e-Pub 2010.
As A, Agarwal N, Siefker-Radtke AO, Roth BJ, Smith DC, Daignault S, Srinivas S, Bradley DA, Hussain M. Targeting epidermal growth factor receptor (EGFR) in urothelial cancer (UC): A phase II randomized trial of cisplatin (C) with gemcitabine (G) with or without cetuximab. 2010 ASCO Annual Meeting, 2010. e-Pub 2010.
Chiong E, Taylor JM, Siefker-Radtke AO, Millikan RE, Urbauer D, McConkey DJ, Grossman HB, Dinney CP, Kamat AM. Micropapillary bladder cancer: comparison of outcomes with up front cystectomy and neoadjuvant chemotherapy. 2009 ASCO GU Symposium, 2009. e-Pub 2009.
Shah JB, Marquis LM, Svatek RS, Papadopoulos JN, Siefker-Radtke AO, Dinney CP, McConkey DJ. The mitiotic spindle apparatus inhibitor AZD4877 holds promise as a novel therapeutic option against human bladder cancer. 2009 ASCO GU Symposium, 2009. e-Pub 2009.
Siefker-Radtke AO, Kamat AM, Williams DL, Tannir NM, Tu S, Pagliaro LC, Dinney CP, Millikan RE. A phase II randomized 4-regimen selection trial incorporating response for sequential chemotherapy in metastatic, unresectable urothelial cancer: Final results from M. D. Anderson Cancer Center. 2009 ASCO GU Symposium, 2009. e-Pub 2009.
McConkey DJ, Svatek R, Siefker-Radtke AO, Choi W, Shah J, Das A, Kwan A, Adam L, Dinney CP. HDAC inhibitors reverse epithelial-to-mesenchymal transition (EMT) and restore sensitivity to EGFR inhibitors in urothelial carcinoma cells. 2009 ASCO GU Symposium, 2009. e-Pub 2009.
Siefker-Radtke AO. A phase II randomized 4-regimen selection trial incorporating response for sequential chemotherapy in metastic, unresectable urothelial cancer: Final results from the MD Anderson Cancer Center. 2009 ASOC GU Symposium, 2009. e-Pub 2009.
Nguyen JM, Shah JB, Svatek RS, Siefker-Radtke AO, Dinney CP, McConkey DJ. The SRC inhibitor AZD0530 induces growth inhibition and migratory arrest of human bladder cancer cell lines. 2009 ASCO GU Symposium, 2009. e-Pub 2009.
Siefker-Radtke AO. A phase II randomized for-regimen selection trial incorporating response for sequential chemotherapy in metastatic, unresectable urothelial cancer: Final results from the MD Anderson Cancer Center. 2009 ASCO Annual Meeting, 2009. e-Pub 2009.
Siefker-Radtke AO, Millikan RE, Kamat AM, Shen Y, Williams DL, Grossman HB, Dinney CP. A phase II trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine (IAG), followed by cisplatin, gemcitabine and ifosfamide (CGI) in locally advanced urothelial cancer (UC): final results from the M. D. Anderson Cancer Center. 2008 ASCO Annual Meeting 26(15S):269s, 2008. e-Pub 2008.
Agarwal PK, Kassouf W, Grossman HB, Munsell MF, Siefker-Radtke AO, Pisters LL, Dinney CP, Kamat AM. Outcome of bladder cancer patients with pN+ disease after preoperative chemotherapy and radical cystectomy. 2008 ASCO GU Symposium, 2008. e-Pub 2008.
Siefker-Radtke AO, Mathew P, Tannir NM, Tu S, Logothetis CL, Papandreou C. Phase I study of weekly intravenous bortezomib plus mitoxantrone in patients with androgen-independent prostate cancer. American Association of Cancer Research Innovations in Prostate Research, 2006. e-Pub 2006.
Zhu K, Pino S, Siefker-Radtke AO, Shalinsky D, Hu-Lowe D, McConkey DJ. AG-013736, a novel VEGF receptor and PDGF receptor inhibitor with potent activity against human bladder carcinoma in vitro and in vivo. J Clin Oncol 24(18S):13109, 2006. e-Pub 2006.
Rodney AJ, Siefker-Radtke AO, Tannir NM, Swisher S, Walsh G, Millikan RE, Pagliaro LC. Treatment outcomes of patients (pts) with primary mediastinal germ cell tumors (PMGCT): The M. D. Anderson Cancer Center (MDACC) experience. J Clin Oncol 24(18S):14538, 2006. e-Pub 2006.
Brown GA, Spiess PE, Bassett RL, Siefker-Radtke AO, Grossman HB, Dinney CP, Kamat AM. Management of primary carcinomas of the male urethra. American Urological Association Annual Meeting, 2006. e-Pub 2006.
Siefker-Radtke AO, Kamat AM, Grossman HB, Williams DL, Dinney CP, Millikan RE. Prospective evidence supporting the utility of neoadjuvant chemotherapy in small cell urothelial cancer: preliminary results from a phase II clinical trial at the M. D. Anderson Cancer Center. American Urological Association Annual Meeting, 2006. e-Pub 2006.
Siefker-Radtke AO, Poulter V, Mathew P, Tu S, Logothetis C, Papandreou C. Preliminary evidence of efficacy and tolerance for weekly intravenous bortezomib plus mitoxantrone in patients with advanced androgen-independent prostate cancer (AIPCa). J Clin Oncol 23(16S):4567, 2005. e-Pub 2005.
Jonasch E, Tu SM, Tannir NM, Pagliaro LC, Mathew P, Siefker-Radtke AO, Wen S, Wen S, General R, Lin SH, Logothetis CJ. Bone-targeted therapy consisting of zoledronate, thalidomide, and gamma interferon in renal cell carcinoma; a phase II study. J Clin Oncol 23(16S), 2005. e-Pub 2005.
McConkey DJ, Papageorgiou A, Lashinger L, Shrader M, Zhu K, Millikan R, Adam L, Bar-Eli M, Siefker-Radtke AO, Dinney CP. Death receptor-based combination therapy in preclinical models of human bladder cancer. 13th SPORE Workshop, 2005. e-Pub 2005.
Tannir NM, Cohen L, Wang X, Ng C, Poulter V, Mathew P, Siefker-Radtke AO, Jonasch E, Pagilaro L, Thall PF, Millikan RE, Logothetis C. A randomized phase III trial of low dose versus intermediate dose interferon alfa (IFN) as front-line therapy in advanced progressive renal cell cancer (RCC). J Clin Oncol 22(14S):407, 2004. e-Pub 2004.
Siefker-Radtke AO, Thall PF, Tannir NM, Tu S, Pagilaro LC, Williams DL, Millikan RE. Implementation of a novel statistical design to evaluate successive treatment course for metastatic transitional cell carcinoma. A Phase II trial at the M. D. Anderson Cancer Center. J Clin Oncol 23(14S):391, 2004. e-Pub 2004.
Abrahams NA, Siefker-Radtke AO, Reyes AO, Ayala AG, Moran CA. Small cell carcinoma of the bladder: A contemporary clinicopathologic study of 51 cases, 2004. e-Pub 2004.
Sweeny P, Millikan R, Donat M, Wood WC, Siefker-Radtke AO, Pettaway CA, Grossman, HB, Dinney CPN, Swanson DA, Pisters LL. Is there a therapeutic Role for Post-Chemotherapy retroperitoneal Lymph node dissection in metastatic transitional cell carcinoma of the bladder?. Journal of Urology 169(6):2113-2117, 2003. e-Pub 2003.
Siefker-Radtke, A, Gee, J, Logothetis, C, Millikan, R. Is there an effective chemotherapy in the treatment of metastatic urachal carcinoma? The M. D. Anderson Experience. Proc Am Soc Clin Oncol 21:2496, 2002. e-Pub 2002.
Siefker-Radtke AO, Walsh G, Swanson D, Logothetis C, Millikan R. Is There a Role for Surgical Resection in the Management of Metastatic Urothelial Cancer? The M. D. Anderson Experience. Proc Am Soc Clin Oncol 20: 2001 20, 2001. e-Pub 2001.
Siefker-Radtke AO, Dinney CP, Abrahams N, Moran C, Pisters L, Grossman HB, Swanson DA. Is there a role for pre-operative chemotherapy in small cell bladder carcinoma? The M. D. Anderson experience. J Urology 169(4), 2000. e-Pub 2000.

Book Chapters

Ibarra Rovira JJ, Kamat A, Siefker-Radtke AO, Kundra V. Urothelial Carcinoma (Bladder Cancer and Upper Tracts). In: Oncologic Imaging: a Multidisciplinary Approach (Second Edition). Second. Elsevier, Pages 309-329, 329.e1-329.e4, 2023.
Ibarra Rovira, JJ, Kamat, A, Siefker-Radtke, AO, Kundra, V. Urothelial Carcinoma (Bladder Cancer and Upper Tracts), 309,329.e1-329,329.e4, 2022.
Siefker-Radtke, Arlene O. Targeted Therapy in Urothelial Cancer. In: Handbook of Targeted Cancer Therapy and Immunotherapy. 3rd. Wolters Kluwer Publishing, 2021.
Dietrich B, Siefker-Radtke AO, Srinivas S, Yu EY. Systemic Therapy for Advanced Urothelial Carcinoma: Current Standards and Treatment Considerations. In: Am Soc Clin Oncol Educ Book. 38. ASCO, 342-353, 2018.
Al-Shamsi, Hansel DE, Siefker-Radtke AO. Uncommon Cancers of the Bladder. In: Textbook of Uncommon Cancer. 5th. Wiley-Blackwell, 41-53, 2017.
SiefkerRadtke, AO. Urachal and Non-Urachal Adenocarcinomas of the Bladder. In: Rare Genitourinary Tumors. Springer International Publishing Switzerland, 2016.
Siefker-Radtke AO, Czerniak BA, Dinney CPN, McConkey DJ. Bladder Cancer. In: In: The MD Anderson Manual of Medical Oncology. 3rd. McGraw-Hill Education, 755-773, 2016.
Balar A, Tagawa ST, Galsky M, Siefker-Radtke AO. Chemotherapy. In: Upper Tract Urothelial Carcinoma. Springer, 2015.
McConkey DJ, Woonyoung C, Ochoa A, Siefker-Radtke AO, Bogdan C, Czerniak B, Dinney CPN. Therapeutic Opportunities in the Intrinsic Subtypes of Muscle-Invasive Bladder Cancer. In: Bladder Cancer, 2015.
Siefker-Radtke AO. Targeted Therapy in Urothelial Cancer. In: Handbook of Targeted Cancer Therapy. Wolters Kluwer Health, 2015.
Siefker-Radtke AO, Dinney CP, Czerniak B, Millikan RE. Bladder Cancer. In: The MD Anderson Manual of Medical Oncology. 3rd. McGraw-Hill, 2015.
Siefker-Radtke AO. Targeted Therapy in Urothelial Cancer. In: Handbook of Targeted Cancer Therapy. Wolters Kluwer Health, 2014.
Svatek RS, Kamat AM, Siefker-Radtke AO, Dinner CPN. Bladder Cancer. In: 60 Years of Survival Outcomes at The University of Texas M. D. Anderson Cancer Center. Springer, 2012.
Siefker-Radtke AO, Czerniak B, Dinney C, Millikan RE. Uncommon Cancers of the Bladder. In: Textbook of Uncommon Cancer. 4th. John Wiley and Sons, 2012.
Efstathiou J, Quinn DI, Stenzl A, Bellmunt J, Cookson MS, Gakis G, Guru K, Heidenreich A, Keegan P, Lerner SP, Messing EM, Sagalowsky AI, Schoenberg MP, Shipley WU, Siefker-Radtke. Muscle-invasive, Presumably Regional, Tumor. In: Bladder Cancer. Second Edition. European Association of Urology, 269 - 342, 2012.
Parwani A, Dinney C, Siefker-Radtke A. Small Cell Urothelial Carcinoma. In: The Urinary Tract. Springer Publishers, 2012.
Siefker-Radtke A. Chemotherapy, Surgical and Radiation Options for Metastatic Bladder Cancer. In: Essentials and Updates in Urinary Oncology. Nova Science, 2012.
Ng C, Siefker-Radtke AO, Kamat A. Bladder Cancer and Upper Tracts. In: Oncologic Imaging: A Multidisciplinary Approach. Elsevier, 311 - 333, 2012.
Siefker-Radtke, AO, Dinney CPN, Czerniak, B, Millikan RE. Bladder Cancer. In: The MD Anderson Manual of Medical Oncology. 2nd. McGraw Hill Medical, 925 - 943, 2011.
Siefker-Radtke AO, Czerniak B, Dinney C, Millikan RE. Uncommon Cancers of the Bladder. In: Textbook of Uncommon Cancer. 3rd ed. John Wiley and Son, 2006.
Siefker-Radtke AO, Dinney CP, Czerniak B, Millikan RE. Bladder Cancer. In: The MD Anderson Manual of Medical Oncology. 1st. McGraw-Hill, 739-756, 2006.

Less

Selected Presentations & Talks

Local Presentations

2023. Bladder Cancer Matters Podcast. Conference. Bladder Cancer Matters Podcast. Houston, TX, US.
2021. Bladder Cancer. Conference. Bladder Cancer. Houston, TX, US.
2020. Personalized Therapy with Erdafitinib: The First BiomarkerTargeted Therapy for Urothelial Cancer. Conference. Personalized Therapy with Erdafitinib: The First BiomarkerTargeted Therapy for Urothelial Cancer. Houston, TX, US.
2019. Personalized Therapy is Here with FGFR3 Targeting Agents. Conference. Personalized Therapy is Here with FGFR3 Targeting Agents. Houston, TX, US.
2019. New Agents/New Approvals: Where Do We Go From Here?. Conference. New Agents/New Approvals: Where Do We Go From Here?. Houston, TX, US.
2017. The Changing Landscape of Systemic Therapy: New Agents and Novel Therapies. Conference. The Changing Landscape of Systemic Therapy: New Agents and Novel Therapies. Houston, TX, US.
2017. Systemic Therapy in Localized Disease Case Discussion: Managing Toxicity. Conference. Systemic Therapy in Localized Disease Case Discussion: Managing Toxicity. Houston, TX, US.
2017. Combination Therapy with Anti CTLA4 and PD1 or PDL1 Inhibition. Conference. Combination Therapy with Anti CTLA4 and PD1 or PDL1 Inhibition. Houston, TX, US.
2015. Give to No T2 Bladder Cancer Patients, There's Always Adjuvant Therapy. Conference. Give to No T2 Bladder Cancer Patients, There's Always Adjuvant Therapy. Houston, TX, US.
2015. Case Presentations: Urothelial Cancer (Panelist). Conference. Case Presentations: Urothelial Cancer (Panelist). Houston, TX, US.
2015. Advances in Chemotherapy and Targeted Therapy for Urothelial Carcinoma. Conference. Advances in Chemotherapy and Targeted Therapy for Urothelial Carcinoma. Houston, TX, US.
2014. Invasive Urothelial Carcinoma (Moderator). Conference. Invasive Urothelial Carcinoma (Moderator). Houston, TX, US.
2014. Optimizing Neoadjuvant Chemotherapy: The Science of Prediction. Conference. Optimizing Neoadjuvant Chemotherapy: The Science of Prediction. Houston, TX, US.
2014. Dancing with Zebras: Survival in the Wild World of Rare Variants and Upper Tract Disease. Conference. Dancing with Zebras: Survival in the Wild World of Rare Variants and Upper Tract Disease. Houston, TX, US.
2014. Case Presentation (Panelist). Conference. Case Presentation (Panelist). Houston, TX, US.
2013. Invasive Urothelial Cancer (Moderator). Conference. Invasive Urothelial Cancer (Moderator). Houston, TX, US.
2013. Novel Chemo Situations and Novel Chemo Options. Conference. Novel Chemo Situations and Novel Chemo Options. Houston, TX, US.
2013. Case Presentations (Panelists). Conference. Case Presentations (Panelists). Houston, TX, US.
2013. Case Presentations (Moderator). Conference. Case Presentations (Moderator). Houston, TX, US.
2013. Controversy: 63 year old man with T3 bladder cancer wants neoadjuvant chemo (Gem/Cis is Best). Conference. Controversy: 63 year old man with T3 bladder cancer wants neoadjuvant chemo (Gem/Cis is Best). Houston, TX, US.
2013. Bladder Cancer Session (Chair). Conference. Bladder Cancer Session (Chair). Houston, TX, US.
2012. Role for Neoadjuvant Therapy and LND for Upper Tract Transitional Cell Carcinoma. Conference. Role for Neoadjuvant Therapy and LND for Upper Tract Transitional Cell Carcinoma. Houston, TX, US.
2012. Treatment of Advanced Disease (Moderator). Conference. Treatment of Advanced Disease (Moderator). Houston, TX, US.
2012. Case Presentation: Superficial Bladder Cancer and Upper Tract Tumors (Panelist). Conference. Case Presentation: Superficial Bladder Cancer and Upper Tract Tumors (Panelist). Houston, TX, US.
2012. Upper Tract Disease (Moderator). Conference. Upper Tract Disease (Moderator). Houston, TX, US.
2012. Case Presentations in Bladder Cancer (Moderator). Conference. Case Presentations in Bladder Cancer (Moderator). Houston, TX, US.
2012. Node Positive Urothelial Cancer: "When to Snip, When to Dip". Conference. Node Positive Urothelial Cancer: "When to Snip, When to Dip". Houston, TX, US.
2011. Neoadjuvant Chemotherapy for Locally Advanced Bladder Cancer. Conference. Neoadjuvant Chemotherapy for Locally Advanced Bladder Cancer. Houston, TX, US.
2010. Radical Cystectomy and the Need for Adjuvant Chemotherapy. Conference. Radical Cystectomy and the Need for Adjuvant Chemotherapy. Houston, TX, US.
2009. A Patient's Guide to Clinical Trials. Conference. A Patient's Guide to Clinical Trials. Houston, TX, US.
2009. Advances in Oncology. Conference. Advances in Oncology. Houston, TX, US.
2009. Toward Information-Rich Clinical Investigations - Multi-course Adaptive Clinical Trials. Conference. Toward Information-Rich Clinical Investigations - Multi-course Adaptive Clinical Trials. Houston, TX, US.
2008. Update on Systemic Therapy for Metastatic Urothelial Carcinoma, Urologic Oncology: Advances in Clinical Practice. Conference. Update on Systemic Therapy for Metastatic Urothelial Carcinoma, Urologic Oncology: Advances in Clinical Practice. Houston, TX, US.
2007. Bladder & Kidney Cancer Multidisciplinary Planning Conference. Conference. Bladder & Kidney Cancer Multidisciplinary Planning Conference. Houston, TX, US.
2007. Challenges and Opportunities in Advanced Bladder Cancer. Conference. Challenges and Opportunities in Advanced Bladder Cancer. Houston, TX, US.
2005. Development of New Agents in the Treatment of Genitourinary Tumors. Conference. Development of New Agents in the Treatment of Genitourinary Tumors. Houston, TX, US.
2005. Is There a Role for Sugery in the Management of Metastatic Urothelial Cancer?. Conference. Is There a Role for Sugery in the Management of Metastatic Urothelial Cancer?. Houston, TX, US.
2004. Diagnosis and Treatment of Urethral Cancer in Men. Conference. Diagnosis and Treatment of Urethral Cancer in Men. Houston, TX, US.
2004. Management of Metastatic Urothelial Cancer. Conference. Management of Metastatic Urothelial Cancer. Houston, TX, US.

Regional Presentations

2024. Beyond Platinum: Current Approaches to Advanced Bladder Cancer. Poster. JAPRO Live 2024. Dallas, Texas, US.
2019. What’s New in the Neoadjuvant Treatment of Urothelial Cancer. Conference. What’s New in the Neoadjuvant Treatment of Urothelial Cancer. Rochester, NY, US.
2017. Immunotherapy - The New Frontier in the Treatment of Urothelial Cancer. Conference. Immunotherapy - The New Frontier in the Treatment of Urothelial Cancer. Seattle, WA, US.
2017. Emerging Therapeutics for Urothelial Cancer. Conference. Emerging Therapeutics for Urothelial Cancer. Seattle, WA, US.
2016. An Overview of Targeted FGFR3 Therapy in Bladder Cancer With Dr. Siefker-Radtke: PracticeUpdate’s ESMO Coverage. Conference. An Overview of Targeted FGFR3 Therapy in Bladder Cancer With Dr. Siefker-Radtke: PracticeUpdate’s ESMO Coverage, DK.
2016. Current Concepts in Managing Rare Histologies in Bladder Cancer With Dr. Siefker-Radtke: PracticeUpdate’s ESMO Coverage. Conference. Current Concepts in Managing Rare Histologies in Bladder Cancer With Dr. Siefker-Radtke: PracticeUpdate’s ESMO Coverage, DK.
2016. Daily News Podcast: Dr. Arlene O. Siefker-Radtke Discusses the Diagnosis and Treatment of Urachal Cancer. Conference. Daily News Podcast: Dr. Arlene O. Siefker-Radtke Discusses the Diagnosis and Treatment of Urachal Cancer, US.
2005. Preliminary Evidence of Efficacy and Tolerance for Weekly Intravenous Bortezomib Plus Mitoxantrone in Patients with Advanced Androgen-Independent Prostate Cancer (AIPCa). Presentation at Poster Discussion Session. Conference. Preliminary Evidence of Efficacy and Tolerance for Weekly Intravenous Bortezomib Plus Mitoxantrone in Patients with Advanced Androgen-Independent Prostate Cancer (AIPCa). Presentation at Poster Discussion Session, US.

National Presentations

2024. Anti-body-drug conjugates: Opportunities and Challenges. Invited. 4th Binaytara Precision Oncology Summit: Current Standards and Emerging Therapies. San Francisco, CA, US.
2024. Role of Systemic Therapy. Invited. The Leo & Anne Albert Institute for Bladder Cancer Care and Research. Kansas City, MO, US.
2023. Erdafitinib vs. chemotherapy in FGFR mutant bladder cancer. Conference. Erdafitinib vs. chemotherapy in FGFR mutant bladder cancer. Colorado Springs, CO, US.
2023. BT8009 Steering Committee. Conference. BT8009 Steering Committee. Boston, MA, US.
2023. NCCN Bladder/Penile Cancer Panel Meeting. Conference. NCCN Bladder/Penile Cancer Panel Meeting. Plymouth, PA, US.
2023. Defining Treatment Lines in Metastatic Urothelial Cancer: Choosing the right targets and combinations at the right time. Conference. Defining Treatment Lines in Metastatic Urothelial Cancer: Choosing the right targets and combinations at the right time. Washington DC, US.
2023. Emerging Therapies in the Treatment of Bladder Cancer. Conference. Emerging Therapies in the Treatment of Bladder Cancer. Orlando, FL, US.
2022. Systemic Therapies in Urothelial Cancer. Conference. LUGPA Education Committee. Chicago, IL, US.
2022. In Patient with Pure T2 UC, PDL1-high, GFR 60 do I need Neoadjuvant Therapy?. Conference. In Patient with Pure T2 UC, PDL1-high, GFR 60 do I need Neoadjuvant Therapy?. New Orleans, LA, US.
2021. Hitting the Target: Selecting Patients for Targeted Therapy in Metastatic Urothelial Cancer. Conference. Hitting the Target: Selecting Patients for Targeted Therapy in Metastatic Urothelial Cancer. Orange, CA, US.
2021. Targeted Oncology Case-based Roundtable Meeting on advanced/Metastatic Bladder Cancer. Conference. Targeted Oncology Case-based Roundtable Meeting on advanced/Metastatic Bladder Cancer. Houston, TX, US.
2021. A review of the research in urothelial cancers presented and published in the last year was provided by Yee Pei Song, Arlene Siefker-Radtke and Rob Jones, chaired by Alison Birtle. Conference. A review of the research in urothelial cancers presented and published in the last year was provided by Yee Pei Song, Arlene Siefker-Radtke and Rob Jones, chaired by Alison Birtle, US.
2021. Target Practice in Urothelial Cancer - Managing ‘Tox’ Outside the Box. Conference. Target Practice in Urothelial Cancer - Managing ‘Tox’ Outside the Box, US.
2021. New Settings for Immune Checkpoint Inhibitors in Urothelial Bladder Cancer. Conference. New Settings for Immune Checkpoint Inhibitors in Urothelial Bladder Cancer, US.
2020. Debate: Surgery Has a Role in Node-Only M1 UC. Conference. Debate: Surgery Has a Role in Node-Only M1 UC, US.
2020. Optimizing Treatment for Advanced Urothelial Cancer: Combination, Maintenance, or Sequencing. Conference. Optimizing Treatment for Advanced Urothelial Cancer: Combination, Maintenance, or Sequencing, US.
2020. Advanced UCa Panel Discussion. Conference. Advanced UCa Panel Discussion, US.
2020. Precision Therapy in Urothelial Cancer: New Approaches in Molecular Enrichment. Conference. ASCO20 Virtual, US.
2020. Phase 3 Study of First-Line Pembrolizumab Plus Lenvatinib in Patients With Advanced Urothelial Carcinoma Ineligible for Platinum-Based Chemotherapy: LEAP-011. Conference. Phase 3 Study of First-Line Pembrolizumab Plus Lenvatinib in Patients With Advanced Urothelial Carcinoma Ineligible for Platinum-Based Chemotherapy: LEAP-011. San Francisco, CA, US.
2019. Third-Line Therapy for Metastatic Bladder Cancer. Conference. 37th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow. New York, NY, US.
2019. Role of Biomarkers in Predicting Response in Urothelial Cancer. Conference. Role of Biomarkers in Predicting Response in Urothelial Cancer. Minneapolis, MN, US.
2019. Development of Bempegaldesleukin with Nivolumab in Urothelial Cancer: Back to the Future with IL-2. Conference. Development of Bempegaldesleukin with Nivolumab in Urothelial Cancer: Back to the Future with IL-2. Minneapolis, MN, US.
2019. Gene expression profiling in wild type and mutant FGFR3 metastatic urothelial cancer treated with combination therapy with vofatamab and pembrolizumab. Conference. Gene expression profiling in wild type and mutant FGFR3 metastatic urothelial cancer treated with combination therapy with vofatamab and pembrolizumab. Denver, CO, US.
2019. NKTR-214 + nivolumab in first-line advanced/metastatic urothelial carcinoma (mUC): Updated results from PIVOT-02. Conference. NKTR-214 + nivolumab in first-line advanced/metastatic urothelial carcinoma (mUC): Updated results from PIVOT-02. San Francisco, CA, US.
2018. Urologic Oncology Presentations. Conference. Urologic Oncology Presentations, US.
2018. Guest Speaker. Conference. Advocacy Network Leadership. Houston, TX, US.
2018. Erdafitinib treatment of bladder cancer. Conference. Erdafitinib treatment of bladder cancer. Kansas City, MO, US.
2018. Molecular Classification and Targeted Therapy. Conference. Molecular Classification and Targeted Therapy. Denver, CO, US.
2018. Role of precision therapy in the treatment of advance urothelial cancer. Conference. Role of precision therapy in the treatment of advance urothelial cancer. Chicago, IL, US.
2018. Nivolumab monotherapy in patients with advanced platinum-resistant urothelial carcinoma: Efficacy and safety update and association between biomarkers and overall survival in CheckMate 275. Conference. Nivolumab monotherapy in patients with advanced platinum-resistant urothelial carcinoma: Efficacy and safety update and association between biomarkers and overall survival in CheckMate 275. Chicago, IL, US.
2018. Moderator on Bladder Cancer, Targeted Oncology Case-Based Peer Perspectives, Targeted Oncology Case-Based Peer Perspectives. Conference. Targeted Oncology. New York City, NY, US.
2018. The Future of FGFR Inhibitors in Urothelial Cancer. Conference. The Future of FGFR Inhibitors in Urothelial Cancer. Baltimore, MD, US.
2017. Molecular Classification of Urothelial Cancers and its Therapeutic Implications. Conference. MD Anderson Cancer Center and MD Anderson Physicians Network Symposium. Houston, TX, US.
2017. Exploring FGFR Inhibition in Urothelial Cancer. Conference. 4th Annual Albert Institute Symposium on Bladder Cancer. Houston, US.
2017. Immunotherapy Side Effects: The Dark/Turquoise Side of the Moon. Conference. Bladder Think Tank. Charlotte, SC, US.
2017. Targeted Oncology Discussion. What’s New in Immunotherapy for Urothelial Cancer: Cased-based Peer Perspectives Dinner Meeting. Conference. Targeted Oncology Discussion. What’s New in Immunotherapy for Urothelial Cancer: Cased-based Peer Perspectives Dinner Meeting. Boston, MA, US.
2017. The Promise of Immunotherapy and Targeted Therapy for Bladder Cancer. Conference. OncLive 2017 State of the Science Summit: Genitourinary Cancers. Houston, TX, US.
2017. Emerging Technologies for Detection and Treatment of Cancer. Conference. U54 Partnership Emerging Technologies Course. San Juan, PR, US.
2016. Nivolumab. Conference. Nivolumab. Denver, CO, US.
2016. FGFR3 pathway over view - previous development. Conference. FGFR3 pathway over view - previous development. Denver, CO, US.
2016. JNJ-42756493. Conference. JNJ-42756493. Denver, CO, US.
2015. Chemotherapy in the Renally Impaired. Conference. Chemotherapy in the Renally Impaired. Washington, DC, US.
2015. The basal subtype to predict clinical benefit from neoadjuvant chemotherapy: Final results from a phase II clinical trial of DDMVAC plus bevacizumab. Conference. The basal subtype to predict clinical benefit from neoadjuvant chemotherapy: Final results from a phase II clinical trial of DDMVAC plus bevacizumab. Orlando, FL, US.
2015. Controversies in the treatment of penile, urethral and testicular cancers (ars) Panelist. Conference. 2015 Genitourinary Cancers Symposium. Orlando, FL, US.
2015. Roundtable Discussion - Controversies in the Treatment of Penile, Urethral and Testicular Cancers. Conference. 2015 Genitourinary Cancers Symposium. Orlando, FL, US.
2015. Fellows, Residents and Junior Faculty Networking Group Table Discussion. Conference. 2015 Genitourinary Cancers Symposium. Orlando, FL, US.
2014. Improving the Delivery of Neoadjuvant Chemotherapy: Where we are and what tools are missing. Conference. Improving the Delivery of Neoadjuvant Chemotherapy: Where we are and what tools are missing. Hartford, CT, US.
2014. Special Situations: Sequences, Neuropathy, Renal Insufficiency, etc. Conference. Special Situations: Sequences, Neuropathy, Renal Insufficiency, etc. Hartford, CT, US.
2014. Emerging Concepts in the Treatment of the Urothelial Carcinoma of the Bladder and the Upper Tract. Conference. Emerging Concepts in the Treatment of the Urothelial Carcinoma of the Bladder and the Upper Tract. Boston, MA, US.
2014. How to Improve Delivery of Neoadjuvant Chemotherapy. Conference. How to Improve Delivery of Neoadjuvant Chemotherapy. Orlando, FL, US.
2014. Gene expression profiling in the context of neoadjuvant chemotherapy with DDMVAC+B (dose dense methotrexate, vinblastine, doxorubicin, cisplatin, and bevacizumab) can predict clinical outcomes and tumor biology. Conference. Gene expression profiling in the context of neoadjuvant chemotherapy with DDMVAC+B (dose dense methotrexate, vinblastine, doxorubicin, cisplatin, and bevacizumab) can predict clinical outcomes and tumor biology. San Diego, CA, US.
2012. A Review of Peri-Operative Chemotherapy in UTUC and Chemotherapy for the Renally-Impaired Patient. Conference. A Review of Peri-Operative Chemotherapy in UTUC and Chemotherapy for the Renally-Impaired Patient. Bethesda, MD, US.
2012. A review of Peri-Operative chemotherapy in UTUC and chemotherapy for the renally-impaired patient. Conference. A review of Peri-Operative chemotherapy in UTUC and chemotherapy for the renally-impaired patient. Rockville, MD, US.
2012. Discussion: Developing a Consensus on Conducting a National, Multicenter Protocol - What is Needed in Terms of Collaborations, Infrastructure and Funding. Conference. Discussion: Developing a Consensus on Conducting a National, Multicenter Protocol - What is Needed in Terms of Collaborations, Infrastructure and Funding. Bethesda, MD, US.
2012. Current and Emerging Strategies in the Management of Bladder Cancer. Conference. Current and Emerging Strategies in the Management of Bladder Cancer. Chicago, US.
2012. Neoadjuvant chemotherapy with DD-MVAC and bevacizumab in high-risk urothelial cancer: Results from a phase II trial at the M. D. Anderson Cancer Center. Conference. 2012 Genitourinary Cancers Symposium. San Francisco, CA, US.
2011. NCI Novel Neoadjuvant Therapy for Bladder Cancer Panel Speaker. Conference. NCI. Gaithersburg, MD, US.
2011. Welcome and General Session IV: Urothelial Carcinomas: Cases in Perioperative Chemotherapy Panel Speaker. Conference. 2011 Genitourinary Cancers Symposium. Orlando, FL, US.
2010. Bladder Cancer Think Tank. Conference. Pfizer Oncology. La Jolla, CA, US.
2010. Emerging agents in Urothelial Cancer. Conference. Bristol Myer Squibb. Philadelphia, PA, US.
2009. Decreasing Mortality from Bladder Cancer over the Next Decade. Conference. AUA Foundation. Linthicum, MD, US.
2009. Treating Urothelial Cancer - Raising the Bar. Conference. NCI Translational Science Meeting. Vienna, VA, US.
2009. Neoadjuvant Chemotherapy for Small Cell Urothelial Cancer: Newfound Hope in a Time of Change. Conference. Cleveland Clinic. Cleveland, OH, US.
2009. Clinical Trial Designs in the Era of Targeted Therapy. Conference. BCAN. Jackson Hole, WY, US.
2009. Novel Agents and the Trials that Love Them: A Developmental Paradigm for Urothelial Cancer, Clinical Research Meeting Seminar Series. Conference. University of New Mexico Cancer Center. Albuquerque, NM, US.
2008. Targets and Agents in Current Phase II Exploratory Trials. Conference. Advancing Treatment of Bladder Cancer - Cambridge Consensus Conference. Boston, MA, US.
2006. Phase I Study of Weekly Intravenous Bortezomib Plus Mitoxantrone in Patients with Androgen-Independent Prostate Cancer. Conference. Innovations in Prostate Cancer Research. San Francisco, CA, US.
2006. Neoadjuvant Therapy for Bladder Cancer - A Platform for Translational Stuides. Conference. 14th SPORE Investigator's Workshop. Baltimore, MD, US.
2006. Genitourinary Cancers, Updates in Oncology: Review from Atlanta and a Look into the Future. Conference. Imedex. New York, NY, US.
2005. Panel. Conference. Vinflunine Genitourinary Advisory Board Meeting. Short Hills, NJ, US.
2004. Panel. Conference. Bristol-Meyer Squibb Javlor (vinflunine) Advisory Board. New York, NY, US.
2003. Is There A Role for Pre-operative Chemotherapy in Small Cell Bladder Carcinoma? The M. D. Anderson Experienc. Conference. 2003 American Urological Association Annual Meeting. Chicago, IL, US.
2002. Is There a Role for Surgical Resection in the Management of Metastatic Urothelial Cancer? An Update of the M. D. Anderson Experience. Conference. American Urological Association Meeting. Orlando, FL, US.
2002. Phase III Trial of 5-Fluorouracil, Alpha-Interferon and Cisplatin (FAP) vs. Methotrexate, Vinblastin, Doxorubicin and Cisplatin (M-VAC) in Metastatic or Unresectable Urothelial Cancer. Poster Presentation. Conference. National Medical Oncology Fellow's Forum. Litchfield Parck, AZ, US.
2001. Is There a Role for Surgical Resection in the Management of Metastatic Urothelial Cancer: The M. D. Anderson Experience. Oral presentation. Conference. 11th Annual Mayo Clinic Hematology/Oncology Reviews. Jacksonville, FL, US.
2001. Is There a Role for Surgical Resection in the Management of Metastatic Urothelial Cancer? The M. D. Anderson Experience. Conference. National Medical Oncology Fellows Forum. Orlando, FL, US.

International Presentations

2024. EV302 Launch. Invited. South Korean Oncologists. Seoul, KR.
2023. 2023 Expert Forum. Conference. 2023 Expert Forum. Washington DC, US.
2023. Phase 3 THOR Study: Results of Erdafitinib (erda) vs Pembrolizumab (pembro) in Pretreated Patients (pts) wit Advanced or Metastatic Urothelial Cancer (mUC) with Select Fibroblast Growth Factor Reeptor Alterations (FGFRalt). Conference. Phase 3 THOR Study: Results of Erdafitinib (erda) vs Pembrolizumab (pembro) in Pretreated Patients (pts) wit Advanced or Metastatic Urothelial Cancer (mUC) with Select Fibroblast Growth Factor Reeptor Alterations (FGFRalt). Madrid, ES.
2023. Erdafitinib (ERDA) vs ERDA plus cetrelimab (ERDA+CET) for patients (pts) with metastatic urothelial carcinoma (mUC) and fibroblast growth factor receptor alterations (FGFRa): Final results from the phase 2 norse study. Conference. Erdafitinib (ERDA) vs ERDA plus cetrelimab (ERDA+CET) for patients (pts) with metastatic urothelial carcinoma (mUC) and fibroblast growth factor receptor alterations (FGFRa): Final results from the phase 2 norse study. Chicago, US.
2023. Thematic Session: Next steps in immunotherapy for GU malignancies. Conference. Thematic Session: Next steps in immunotherapy for GU malignancies. Milan, IT.
2022. Janssen’s Balversa Product Training. Conference. Janssen’s Balversa Product Training. Oaxaca, MX.
2022. Bladder cancer management session: Treating NMIBC, MIBC, and mUC patients today and in the future. Conference. Bladder cancer management session: Treating NMIBC, MIBC, and mUC patients today and in the future. São Paulo, BR.
2022. Adjuvant therapy for MIBC: Does approval of nivolumab in the adjuvant setting change indication for NAC? T2HG MIBC no adverse histology or LVI etc, imaging clean, otherwise healthy patient, GFR 68. Conference. Adjuvant therapy for MIBC: Does approval of nivolumab in the adjuvant setting change indication for NAC? T2HG MIBC no adverse histology or LVI etc, imaging clean, otherwise healthy patient, GFR 68. Amsterdam, NL.
2022. Precision medicine in uro-oncology. Conference. Precision medicine in uro-oncology. São Paulo, BR.
2021. Bladder Cancer: A Booming Year? A review of the research in urothelial cancers presented and published in the last year. Conference. Bladder Cancer: A Booming Year? A review of the research in urothelial cancers presented and published in the last year, GB.
2021. Oral Abstract Session: Urothelial Carcinoma; and Adrenal, Penile, Testicular, and Urethral Cancers. Conference. Oral Abstract Session: Urothelial Carcinoma; and Adrenal, Penile, Testicular, and Urethral Cancers, US.
2021. Moderated Panel Discussion with Drs. Balar, Daneshmand, Holzbeierlein, Huddart, Powles and Siefker-Radtke. Conference. Moderated Panel Discussion with Drs. Balar, Daneshmand, Holzbeierlein, Huddart, Powles and Siefker-Radtke, US.
2020. Recent Advances in Medical Oncology: Urothelial Bladder Carcinoma. Conference. ASCO Bladder Live Webcast, US.
2019. Personalized Therapy with ERdafitinib: The First Biomarker Targeted Therapy for Urothelial Cancer. Conference. Personalized Therapy with ERdafitinib: The First Biomarker Targeted Therapy for Urothelial Cancer. Sao Paolo, BR.
2019. Novel Agents Under Development of Metastatic Urothelial Cancer. Conference. Novel Agents Under Development of Metastatic Urothelial Cancer. Sao Paolo, BR.
2018. Role of Precision Therapy in the Treatment of Advanced Urothelial Cancer. Conference. American Society of Clinical Oncology Annual Meeting. Chicago, US.
2018. First results from the primary analysis population of the phase 2 study of erdafitinib (ERDA; JNJ-42756493) in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR alterations (FGFRalt). Conference. First results from the primary analysis population of the phase 2 study of erdafitinib (ERDA; JNJ-42756493) in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR alterations (FGFRalt). Chicago, US.
2018. Fibroblast growth factor receptor 3 (FGFR3), peroxisome proliferator-activated receptor gamma (PPARg), and outcomes with nivolumab (nivo) in metastatic urothelial cancer (UC). Conference. Fibroblast growth factor receptor 3 (FGFR3), peroxisome proliferator-activated receptor gamma (PPARg), and outcomes with nivolumab (nivo) in metastatic urothelial cancer (UC). San Francisco, US.
2018. A new 50-gene molecular subtype classifier: An evaluation of subtype stability and association with response to neoadjuvant chemotherapy in muscle-invasive bladder cancer. Conference. A new 50-gene molecular subtype classifier: An evaluation of subtype stability and association with response to neoadjuvant chemotherapy in muscle-invasive bladder cancer. San Francisco, US.
2018. Efficacy of programmed death 1 (PD-1) and programmed death 1 ligand (PD-L1) inhibitors in patients with FGFR alterations: results from a data analysis of an ongoing Phase 2 study of erdafitinib (JNJ-42756493) in patients (pts) with advanced urothelial cancer (UC). Conference. Efficacy of programmed death 1 (PD-1) and programmed death 1 ligand (PD-L1) inhibitors in patients with FGFR alterations: results from a data analysis of an ongoing Phase 2 study of erdafitinib (JNJ-42756493) in patients (pts) with advanced urothelial cancer (UC). San Francisco, US.
2018. Erdafitinib (ERDA; JNJ-42756493), a pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR alterations (FGFRa): Phase 2 continuous versus intermittent dosing. Conference. Erdafitinib (ERDA; JNJ-42756493), a pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR alterations (FGFRa): Phase 2 continuous versus intermittent dosing. San Francisco, US.
2018. Dynamic Duo or Double Trouble: Combination Immunotherapy in Metastatic Renal Cell Carcinoma. Conference. Dynamic Duo or Double Trouble: Combination Immunotherapy in Metastatic Renal Cell Carcinoma. Chunghua, TW.
2018. Immunotherapy in Genitourinary Cancers: The Next Frontier. Conference. Immunotherapy in Genitourinary Cancers: The Next Frontier. Chunghua, TW.
2018. Predicting Response to Immunotherapy in Metastatic Urothelial Cancer. Conference. Predicting Response to Immunotherapy in Metastatic Urothelial Cancer. Chunghua, TW.
2016. GU Oncology Session. Conference. 4th International Conference on Advances in Hematology and Oncology. Coeur d'Alene, US.
2013. Systemic therapy for Metastatic Bladder Cancer: Are we making any progress?. Conference. Systemic therapy for Metastatic Bladder Cancer: Are we making any progress?. Amman, JO.
2013. Adjuvant/ neoadjuvant chemotherapy for muscle invasive TCC of bladder & upper tract. Conference. Adjuvant/ neoadjuvant chemotherapy for muscle invasive TCC of bladder & upper tract. Amman, JO.
2013. Management of rare Bladder Cancer Histologies. Conference. Management of rare Bladder Cancer Histologies. Amman, JO.
2012. Emerging Concepts in the Multidisciplinary Management of Urothelial Cancer. Conference. Emerging Concepts in the Multidisciplinary Management of Urothelial Cancer. San Juan, PR.
2012. Metastatic Urothelial Cancer - systemic therapy. Conference. Metastatic Urothelial Cancer - systemic therapy. Sao Paulo, BR.
2012. Localized Prostate Cancer. Conference. Localized Prostate Cancer. Sao Paula, BR.
2012. Biochemical Relapse after local treatment for Prostate Cancer. Conference. Biochemical Relapse after local treatment for Prostate Cancer. Sao Paulo, BR.
2012. Metastatic Castration Resistant Prostate Cancer. Conference. Metastatic Castration Resistant Prostate Cancer. Sao Paulo, BR.
2012. Penile Cancer - Initial Management. Conference. Penile Cancer - Initial Management. Sao Paulo, BR.
2012. Neo-adjuvant Chemotherapy in Urothelial Cancer. Conference. Neo-adjuvant Chemotherapy in Urothelial Cancer. Sao Paulo, BR.
2009. Multi-Course Adaptive Clinical Trials in Urothelial Cancer - Where the Art of Patient Care Melds with the Science of Trial Design. Conference. Taiwan Cooperative Oncology Group. Taipei, TW.
2009. A Phase II Randomized Four-Regimen Selection Trial Incorporating Response for Sequential Chemotherapy in Metastatic, Unresectable Urothelial Cancer: Final Results from the M. D. Anderson Cancer Center. Conference. A Phase II Randomized Four-Regimen Selection Trial Incorporating Response for Sequential Chemotherapy in Metastatic, Unresectable Urothelial Cancer: Final Results from the M. D. Anderson Cancer Center. Orlando, US.
2008. A Phase II Trial of Sequential Neoadjuvant Chemotherapy with Ifosfamide, Doxorubicin, and Gemcitabine (IAG), followed by Cisplatin, Gemcitabine and Ifosfamide (CGI) in Locally Advanced Urothelial Cancer (UC): Final Results from the M. D. Anderson Cancer Center. Conference. American Society of Clinical Oncology Annual Meeting. Chicago, US.
2007. Adjuvant Low-Dose Interleukin-2 (IL-2) plus Interferon-Alpha (IFN-alpha) in Operable Renal Cell Cancer (RCC): A Phase III, Randomized, Multicenter, Independent Trial of the Italian Oncology Group for Clinical Research (GOIRC) - Invited Dicussant. Conference. American Society of Clinical Oncology Annual Meeting. Chicago, US.
2007. Randomized Phase III Study Comparing Paclitaxel/Cisplatin/Gemcitabine (PCG) and Gemcitabine/Cisplatin (GC) in Patients with Locally Advanced (LA) or Metastatic (M) Urothelial Cancer without Prior Systemic Therapy: EORTC30987/Intergroup- Invited Discussant. Conference. American Society of Clinical Oncology Annual Meeting. Chicago, US.
2005. Challenging Cases in the Treatment of Genitourinary Tumors. Conference. The Second Curso de Manejo Clinico Multidisciplinar en el Pacienter Con Cancer. Madrid, ES.
2005. Advances in the Management of Metastatic Urothelial Cancer. Conference. Saarland University. Hombury-Saar, DE.
2005. Is there a Role for Surgery in the Management of Metastatic Urothelial Cancer? Urology Grand Rounds. Conference. Saarland University. Homburg-Saar, DE.
2005. A Potential Role for Surgical Resection in Metastatic Urothelial Cancer. Conference. 57th Kongress der Deutschen Gesellschaft fur Urologie. Dusseldorf, DE.
2005. Preliminary Evidence of Efficacy and Tolerance for Weekly Intravenous Bortezomib Plus Mitoxantrone in Patients with Advanced Androgen-Independent Prostate Cancer (AIPCa). Conference. Discussion Session at the 2005 ASCO Annual Meeting. Proceedings of ASCO, US.
2004. Panel. Conference. Panel, US.
2004. Implementation of a Novel Statistical Design to Evaluate Successive Treatment Course for Metastatic Transitional Cell Carcinoma. A phase II trial at the M. D. Anderson Cancer Center. Conference. 2004 American Society of Clinical Oncology Annual Meeting Discussion Session. New Orleans, US.
2001. Is There a Role for Surgical Resection in the Management of Metastatic Urothelial Cancer? The M. D. Anderson Experience. Conference. Discussion Session at the 2001 ASCO Annual Meeting. San Francisco, US.

Formal Peers

2022. Tufts Medical Center: Cancer Center Grand Rounds. Invited. Tufts Medical Center: Cancer Center Grand Rounds, US.
2021. URMC Bladder Cancer Symposium 2021: Urothelial Cancer: Upper Tract Urothelial Cancer. Invited. URMC Bladder Cancer Symposium 2021: Urothelial Cancer: Upper Tract Urothelial Cancer. Rochester, NY, US.
2021. Hitting the Target: Selecting Patients for Targeted Therapy in Metastatic Urothelial Cancer. Invited. Hitting the Target: Selecting Patients for Targeted Therapy in Metastatic Urothelial Cancer. Orange, CA, US.
2021. Erdafitinib: The first FGFR3 targeted therapy for metastatic urothelial carcinoma. Invited. Erdafitinib: The first FGFR3 targeted therapy for metastatic urothelial carcinoma. Seattle, WA, US.
2020. Personalized Therapy with Erdafitinib: The First Biomarker-Targeted Therapy for Urothelial Cancer. Invited. Personalized Therapy with Erdafitinib: The First Biomarker-Targeted Therapy for Urothelial Cancer. Charlotte, NC, US.
2019. Bladder Cancer. Invited. Bladder Cancer. Houston, TX, US.
2019. Bladder Cancer. Invited. Bladder Cancer. Houston, TX, US.
2018. The Future of FGFR Inhibitors in Urothelial Cancer - Biology and Therapy of Non-Muscle Invasive Bladder Cancer. Invited. The Future of FGFR Inhibitors in Urothelial Cancer - Biology and Therapy of Non-Muscle Invasive Bladder Cancer. Baltimore, MD, US.
2016. Oncology Grand Rounds. Invited. Oncology Grand Rounds. Lake Success, NY, US.
2016. Immune Checkpoint Inhibitors in the Treatment of Selected Tumor Types: A New Direction. Invited. Immune Checkpoint Inhibitors in the Treatment of Selected Tumor Types: A New Direction. Houston, TX, US.
2016. Muscle-invasive and Metastatic Bladder Cancer. Invited. Muscle-invasive and Metastatic Bladder Cancer. Houston, TX, US.
2015. Bladder Carcinoma. Invited. Bladder Carcinoma. Houston, TX, US.
2014. Treatment of variant histology in urothelial cancer. Invited. Treatment of variant histology in urothelial cancer. Houston, TX, US.
2013. Bladder Carcinoma. Invited. Bladder Carcinoma. Houston, TX, US.
2008. Bladder Cancer Basics. Invited. Bladder Cancer Basics. Houston, TX, US.
2006. Cisplatin-Related Nephrotoxicity in the Bladder Cancer Patient. Invited. Cisplatin-Related Nephrotoxicity in the Bladder Cancer Patient. Houston, TX, US.
2005. Urothelial Cancer. Visiting. Urothelial Cancer. Homburg-Saar, DE.
2005. Is There a Role for Surgery in the Management of Metastatic Urothelial Cancer. Invited. Is There a Role for Surgery in the Management of Metastatic Urothelial Cancer. Houston, TX, US.
2004. Diagnosis and Treatment of Urethral Cancer in Men. Invited. Diagnosis and Treatment of Urethral Cancer in Men. Houston, TX, US.
2004. Multimodality Management of Invasive Transitional Cell Carcinoma. Invited. Multimodality Management of Invasive Transitional Cell Carcinoma. Houston, TX, US.
2004. Management of Metastatic Urothelial Cancer. Invited. Management of Metastatic Urothelial Cancer. Houston, TX, US.

Less

Grant & Contract Support

Date:	2019 - 2024
Title:	SPORE in Genitourinary Cancer - Project 3: Characterizing Immune Microenvironment Response to Chemotherapy and Immune Checkpoint Blockade
Funding Source:	NIH/NCI
Role:	Co-Program Leader
ID:	P50 CA091846-16

Date:	2018 - 2019
Title:	SPORE in Genitourinary Cancers
Funding Source:	NIH/NCI
Role:	Clinical Project Co-Leader
ID:	3P50CA091846-15S1

Date:	2017 - 2022
Title:	RNA Sequencing and Tumor Sub-typing for the Open Label Phase 1b Study of Novel FGFR3 Inhibitor (B-701) Combined with Atezolizumab in Subjects with Locally Advanced or Metastatic Urothelial Carcinoma who Have Progressed Following Platinum-based Chemotherapy
Funding Source:	BioClin Therapeutics, Inc
Role:	PI
ID:	2017-0580

Date:	2017 - 2019
Title:	RNAseq and Tumor Subtyping
Funding Source:	Janssen Pharmaceuticals, Inc
Role:	PI
ID:	53900

Date:	2016 - 2018
Title:	Targeting FGFR3 in Muscle-Invasive Bladder Cancer
Funding Source:	The JPB Foundation Bladder Cancer Research Innovation Award
Role:	Co-I
ID:	No Number

Date:	2014 - 2017
Title:	Defining the biological and clinical properties of the p53-like/luminal A subtype for bladder cancer
Funding Source:	The V Foundation for Cancer Research
Role:	Co-I
ID:	No Number

Date:	2014 - 2017
Title:	Biology and Therapy of Basal Bladder Cancers
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Co-I
ID:	RP140542

Date:	2011 - 2016
Title:	SPORE in Genitourinary Cancer
Funding Source:	NIH/NCI
Role:	Co-I
ID:	2P50 CA91846

Date:	2010 - 2010
Title:	Targeted Therapy in Bladder Cancer
Funding Source:	AstraZeneca
Role:	Co-PI
ID:	LS2009-00028520

Date:	2009 - 2011
Title:	TRAIL receptor-based combination therapy for androgen-independent prostate cancer
Funding Source:	DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP)
Role:	Co-I
ID:	PC074306P1

Date:	2008 - 2013
Title:	Targeting the erbB Family in Bladder Cancer
Funding Source:	NIH/NCI
Role:	Co-I

Date:	2006 - 2012
Title:	Biology and Therapeutic Targeting of Epidermal Growth Factor Receptor in Bladder Cancer
Funding Source:	NIH/NCI
Role:	Clinical Co-Leader
ID:	5 P50 CA091846 10

Date:	2004 - 2005
Title:	Translational Studies Characterizing EGFR Signaling in the Context of Consolidative Therapy with Iressa and Taxotere for Metastatic Urothelial Carcinoma: A Companion Laboratory Study for 2003-0767
Funding Source:	The University of Texas M. D. Anderson Cancer Center SPORE Grant
Role:	PI

Title:	Biological and Therapeutical Implications of miR-200c in Bladder Cancer
Funding Source:	American Association for Cancer Research (AACR)
Role:	Co-I

CV information above last modified April 04, 2025

Arlene O Siefker-Radtke, MD

In the News

ASCO: Targeted therapy achieves responses across multiple cancer types with FGFR alterations

Can frequent UTIs be a sign of bladder cancer?

ASCO: Updated targeted therapy clinical trials results continue to show improved outcomes for advanced colorectal and bladder cancers

New drug brings new hope for advanced bladder cancer

Present Title & Affiliation

Primary Appointment

Dual/Joint/Adjunct Appointment

Research Interests

Education & Training

Degree-Granting Education

Postgraduate Training

Board Certifications

Experience & Service

Academic Appointments

Administrative Appointments/Responsibilities

Other Appointments/Responsibilities

Institutional Committee Activities

Honors & Awards

Professional Memberships

Selected Publications

Peer-Reviewed Articles

Invited Articles

Manuals, Teaching Aids, Other Teaching Publications

Other Articles

Editorials

Abstracts

Book Chapters

Selected Presentations & Talks

Local Presentations

Regional Presentations

National Presentations

International Presentations

Formal Peers

Grant & Contract Support

Patient Reviews

Request an Appointment

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Clinical Trials

Help #EndCancer

Give Now

Donate Blood

Volunteer